{"response_id": "kimi-k2.5:cloud|GEN-SM-02", "question_id": "GEN-SM-02", "pair_id": "GEN-02", "category": "Generative Design Strategies", "domain": "small_molecule", "question_text": "Why do graph-based molecular generators often yield higher validity rates than naive character-level SMILES generators?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " Graph-based molecular generators achieve higher validity rates (typically **>90–95%** vs. **60–80%** for naive character-level SMILES models) because they encode chemical constraints directly into the generation process, whereas SMILES generators must learn complex, error-prone linear syntax rules.\n\n**Key reasons:**\n\n1. **Explicit valence and bonding constraints**  \n   Graph generators construct molecules by predicting node (atom) types and edge (bond) adjacency matrices. They can enforce hard chemical rules during generation—e.g., carbon cannot exceed four bonds, or nitrogen cannot form five single bonds—ensuring atom-wise validity at each step. In contrast, character-level SMILES models generate linear strings (e.g., `C1=CC=CC=C1`) and frequently violate valence rules or produce chemically impossible connectivity (e.g., pentavalent carbon) because they lack explicit chemical constraints in the decoding logic.\n\n2. **Ring closure and branching syntax**  \n   SMILES requires matched pairs of ring-closure digits (e.g., `C1...C1`) and balanced parentheses for branches. Character-level LSTMs/Transformers often fail to capture these long-range dependencies, generating unmatched indices (e.g., `C1CCCCC`) or invalid nesting. Graph generators explicitly define cycles through edges in the adjacency matrix, eliminating the \"syntax error\" class of invalidity entirely.\n\n3. **Robustness to minor perturbations**  \n   In SMILES, a single character change (e.g., altering `C` to `N` or", "latency_ms": 18656, "timestamp": "2026-02-09T07:37:29.485245+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|GEN-PEP-01", "question_id": "GEN-PEP-01", "pair_id": "GEN-01", "category": "Generative Design Strategies", "domain": "peptide", "question_text": "In sequence-based peptide generation, what makes a generated peptide sequence syntactically valid, and what additional constraint is often imposed for therapeutic developability?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 28399, "timestamp": "2026-02-09T07:40:12.378754+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|GEN-PEP-01", "question_id": "GEN-PEP-01", "pair_id": "GEN-01", "category": "Generative Design Strategies", "domain": "peptide", "question_text": "In sequence-based peptide generation, what makes a generated peptide sequence syntactically valid, and what additional constraint is often imposed for therapeutic developability?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 18326, "timestamp": "2026-02-09T07:47:20.204212+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|ASSAY-PEP-06", "question_id": "ASSAY-PEP-06", "pair_id": "ASSAY-06", "category": "Assay Interpretation", "domain": "peptide", "question_text": "An antimicrobial peptide has MIC = 5 µg/mL and hemolysis HC50 = 25 µg/mL. Compute TI (HC50/MIC) and state why this is a concern and one design direction to reduce hemolysis.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **TI = 5** (25 µg/mL ÷ 5 µg/mL).\n\n**Concern:** This indicates a narrow therapeutic window. The concentration required for antimicrobial efficacy is only 5-fold lower than that causing 50% red blood cell lysis, creating a high risk of hemolytic toxicity at therapeutic doses. Selectivity is poor; desirable AMPs typically have TI > 10–100 (preferably >100).\n\n**Design direction:** **Reduce hydroph", "latency_ms": 14696, "timestamp": "2026-02-09T07:48:08.654085+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|SAR-PEP-05", "question_id": "SAR-PEP-05", "pair_id": "SAR-05", "category": "SAR Reasoning", "domain": "peptide", "question_text": "A peptide’s backbone NH at a specific position donates a critical hydrogen bond to the target (distance ~2.9 Å). What is the expected effect on activity of N-methylating that backbone amide at the same position, and what secondary benefit might occur?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **Expected effect on activity:** Significant reduction or complete loss of binding affinity (and thus activity). N-methylation replaces the backbone N–H with N–CH₃, abolishing the hydrogen bond donor. Since the N–H donates a critical H-bond (2.9 Å is optimal geometry, contributing roughly **1–3 kcal/mol** to binding), removing it typically increases the dissociation constant (K<sub>d</sub>) by **10- to 100-fold** or greater, depending on whether the interaction is solvent-exposed or buried.\n\n**Secondary benefit:** Enhanced **proteolytic stability** and potential improvement in **membrane permeability**. N-methylation masks the amide bond from recognition by peptidases, slowing enzymatic degradation. It also reduces the number of hydrogen bond donors (HBDs), which can improve passive diffusion across lipid membranes and align better with Lipinski/Veber rules for oral bioavailability.", "latency_ms": 36164, "timestamp": "2026-02-09T07:50:51.290880+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|OPT-PEP-03", "question_id": "OPT-PEP-03", "pair_id": "OPT-03", "category": "Optimization Approaches", "domain": "peptide", "question_text": "In phage display affinity maturation, name two experimental knobs that increase selection stringency across rounds and explain the expected effect on the enriched pool.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " Two experimental knobs to increase selection stringency in phage display affinity maturation are:\n\n**1. Decreasing antigen concentration**  \nReducing the coating concentration of target antigen from typical starting levels (e.g., 10–100 nM or 1–10 µg/mL) to sub-nanomolar concentrations (e.g., 0.1–1 nM) in later rounds. At lower antigen densities, only phage displaying binders with high affinity (low nanomolar to picomolar *K*<sub>d</sub>) can effectively compete for limited binding sites, while low-affinity clones (micromolar *K*<sub>d</sub>) are lost due to mass-action effects.\n\n**2. Increasing wash stringency**  \nEscalating the number, duration, or harshness of washing steps (e.g., progressing from 3 brief washes to 5–10 extended washes with high-salt buffers [0.5–1 M NaCl], detergents [0.1–0.5% Tween-20], or chaotropic agents). This applies selective pressure for slow off-rates (*k*<sub>off</sub>), dissociating unstable phage-antigen complexes and enriching for clones with higher binding stability.\n\n**Expected effect on the enriched pool:**  \nThe pool shifts from polyclonal, moderate-", "latency_ms": 18184, "timestamp": "2026-02-09T07:52:17.877801+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|GEN-SM-06", "question_id": "GEN-SM-06", "pair_id": "GEN-06", "category": "Generative Design Strategies", "domain": "small_molecule", "question_text": "Name two generation-time techniques that increase diversity of generated small molecules and one quantitative metric commonly used to measure diversity in molecular sets.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " Two generation-time techniques that increase molecular diversity are:\n\n1. **Temperature sampling** – increasing the softmax temperature parameter (T > 1.0, typically 1.2–1.5) during decoding from generative models (e.g., SMILES-based RNNs or transformers) to flatten the probability distribution and sample less likely tokens.\n2. **Diverse beam search** – modifying standard beam search with diversity penalties (e.g., hamming diversity or rank-based penalties) that discourage similar sequences from occupying multiple beam slots, forcing exploration of disparate chemical spaces.\n\nOne quantitative metric commonly used is **Internal", "latency_ms": 14720, "timestamp": "2026-02-09T07:52:35.598600+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|SAR-PEP-01", "question_id": "SAR-PEP-01", "pair_id": "SAR-01", "category": "SAR Reasoning", "domain": "peptide", "question_text": "A peptide ligand has a Leu side chain that inserts into a hydrophobic subpocket adjacent to an aromatic residue that can support edge-to-face π interactions. If the Leu-containing peptide has Kd = 200 nM, what is the most likely binding change when substituting that Leu with Phe, and why?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 22933, "timestamp": "2026-02-09T07:55:08.661030+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|OPT-SM-06", "question_id": "OPT-SM-06", "pair_id": "OPT-06", "category": "Optimization Approaches", "domain": "small_molecule", "question_text": "A small molecule inhibits both the intended kinase and a close off-target kinase. Structural data indicate the intended target has a larger lipophilic pocket extension that the off-target lacks. What modification strategy is most likely to improve selectivity, and why?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **Strategy:** Add a lipophilic substituent (e.g., alkyl, aryl, or cycloalkyl group) that projects into the extended lipophilic pocket present in the intended target but absent in the off-target.\n\n**Why:** This exploits the structural difference through steric and hydrophobic complementarity. The added group forms favorable van der Waals interactions within the larger pocket of the intended target, maintaining or improving potency. In the off-target, which lacks this cavity, the same substituent causes steric clash or unfavorable desolvation without compensating interactions, reducing binding affinity. \n\n**Typical implementation:** Extension from a solvent-exposed region of the inhibitor scaffold with groups like isopropyl, cyclopropyl, phenyl, or gem-dimethyl groups—often increasing lipophicity (clogP) by 0.5–2.0 units while improving selectivity ratios 10–100-fold. This approach is exemplified by selective CDK4/6 inhibitors (e.g., palbociclib) or BTK inhibitors that exploit unique hydrophobic pockets adjacent to the ATP-binding site.", "latency_ms": 30251, "timestamp": "2026-02-09T07:55:41.912889+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|SAR-PEP-08", "question_id": "SAR-PEP-08", "pair_id": "SAR-08", "category": "SAR Reasoning", "domain": "peptide", "question_text": "A peptide binds as an α-helix but is mostly disordered in solution. Stapling increases preorganization and improves binding free energy by ~1.0 kcal/mol. Approximately what fold-improvement in affinity would you expect at 298 K, and what is the mechanism?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 14324, "timestamp": "2026-02-09T07:58:12.636178+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|OPT-SM-10", "question_id": "OPT-SM-10", "pair_id": "OPT-10", "category": "Optimization Approaches", "domain": "small_molecule", "question_text": "You have four compounds with (IC50 nM, solubility µM, clearance mL/min/kg): A(10, 5, 40), B(30, 50, 20), C(15, 10, 10), D(50, 200, 60). Objectives: minimize IC50 and clearance, maximize solubility. Which compounds are Pareto-optimal?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 37214, "timestamp": "2026-02-09T08:00:38.502087+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|OPT-PEP-07", "question_id": "OPT-PEP-07", "pair_id": "OPT-07", "category": "Optimization Approaches", "domain": "peptide", "question_text": "Cyclization improves a peptide’s protease stability but reduces affinity because the ring distorts the bioactive geometry. What optimization lever can restore affinity while keeping most of the stability gain, and why?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 19659, "timestamp": "2026-02-09T08:03:09.875601+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|SAR-SM-06", "question_id": "SAR-SM-06", "pair_id": "SAR-06", "category": "SAR Reasoning", "domain": "small_molecule", "question_text": "A kinase inhibitor relies on a heteroaromatic ring to form two hinge hydrogen bonds (one acceptor and one donor). What is the most likely potency effect of replacing that heteroaromatic ring with a phenyl ring at the same position, and why?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **Significant potency loss—typically 10- to >1000-fold (ΔΔG ≈ 2–6 kcal/mol).**\n\n**Why", "latency_ms": 15292, "timestamp": "2026-02-09T08:03:28.167959+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|GEN-PEP-08", "question_id": "GEN-PEP-08", "pair_id": "GEN-08", "category": "Generative Design Strategies", "domain": "peptide", "question_text": "In structure-conditioned peptide design for a binding groove, what is typically held fixed vs optimized (backbone vs side chains), and what quantitative structural metric can verify that the designed peptide matches the intended fold?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 13586, "timestamp": "2026-02-09T08:05:50.503055+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|GEN-SM-09", "question_id": "GEN-SM-09", "pair_id": "GEN-09", "category": "Generative Design Strategies", "domain": "small_molecule", "question_text": "List four quantitative metrics commonly used to evaluate small-molecule generative models and briefly state what each measures.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " Here are four standard quantitative metrics used to evaluate generative models for small molecules:\n\n1. **Validity**: The percentage of generated structures that are chemically valid (e.g., correct valency, no chemically impossible bonds, proper aromaticity). Typically reported as 0–100%, with high-performing models achieving >90%.\n\n2. **Uniqueness**: The percentage of valid generated molecules that are distinct from one another (cal", "latency_ms": 19313, "timestamp": "2026-02-09T08:06:12.817044+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|OPT-SM-07", "question_id": "OPT-SM-07", "pair_id": "OPT-07", "category": "Optimization Approaches", "domain": "small_molecule", "question_text": "Adding a fluorine to block a metabolic soft spot increases cLogP from 2.5 to 3.5. What developability risk commonly increases as cLogP rises by ~1 unit, and name one mitigation approach that does not remove the fluorine.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 12471, "timestamp": "2026-02-09T08:08:29.547934+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|GEN-PEP-03", "question_id": "GEN-PEP-03", "pair_id": "GEN-03", "category": "Generative Design Strategies", "domain": "peptide", "question_text": "A peptide binder design strategy fixes a short epitope (e.g., 4 residues) and generates sequences by varying flanking positions. Why can this improve success rates, and what constraint is commonly applied to keep candidates developable?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 34266, "timestamp": "2026-02-09T08:11:08.885448+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|GEN-SM-05", "question_id": "GEN-SM-05", "pair_id": "GEN-05", "category": "Generative Design Strategies", "domain": "small_molecule", "question_text": "You condition a generator to maximize a QSAR-predicted property (e.g., potency) using classifier guidance. What is a common failure mode of this approach, and what is one practical way to detect it?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 17600, "timestamp": "2026-02-09T08:13:54.899561+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|ASSAY-SM-07", "question_id": "ASSAY-SM-07", "pair_id": "ASSAY-07", "category": "Assay Interpretation", "domain": "small_molecule", "question_text": "Three analogs have (IC50 nM, kinetic solubility µM): A(30, 2), B(80, 50), C(20, 0.5). If you require IC50 ≤ 50 nM and solubility ≥ 5 µM for the next round, which analog best meets criteria and what is the most logical next experimental step?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 13370, "timestamp": "2026-02-09T08:16:14.847503+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|OPT-SM-09", "question_id": "OPT-SM-09", "pair_id": "OPT-09", "category": "Optimization Approaches", "domain": "small_molecule", "question_text": "A baseline inhibitor has IC50 = 1.0 µM. Substitution A gives IC50 = 0.30 µM, substitution B gives IC50 = 0.20 µM, and the double substitution AB gives IC50 = 0.020 µM. Under a multiplicative (log-additive) model, what IC50 would you predict for AB, and does the observation indicate positive epistasis (synergy)?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " Under a multiplicative model, the predicted IC50 for the double substitution AB is **0.060 µM** (60 nM).\n\n**Calculation:**\n- Fold improvement for A: 1.0 µM / 0.30 µM = 3.3-fold\n- Fold improvement for B: 1.0 µM / 0.20 µM = 5.0-fold  \n- Predicted combined fold improvement: 3.3 × 5.0 = 16.7-fold\n- Predicted IC50: 1.0 µM / 16.7 = **0.060 µM** (or 1.0 µM × 0.30 × 0.20)\n\n**Epistasis determination:**\n**Yes, this indicates positive epistasis (synergy).** The observed IC50 (0.020 µM) is 3-fold", "latency_ms": 16687, "timestamp": "2026-02-09T08:16:34.535148+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|ADMET-PEP-09", "question_id": "ADMET-PEP-09", "pair_id": "ADMET-09", "category": "ADMET / Pharmacokinetic Properties", "domain": "peptide", "question_text": "In an in vivo PK study, a peptide shows accelerating clearance over repeated weekly dosing despite similar initial exposure. What two mechanisms can cause this, and what measurements distinguish them?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 20810, "timestamp": "2026-02-09T08:18:59.610607+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|ADMET-SM-06", "question_id": "ADMET-SM-06", "pair_id": "ADMET-06", "category": "ADMET / Pharmacokinetic Properties", "domain": "small_molecule", "question_text": "A candidate has TPSA = 140 Å², HBD = 3, and is a P-gp substrate. Name two design strategies that can increase oral absorption and briefly explain the mechanism.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 27353, "timestamp": "2026-02-09T08:21:37.877608+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|ADMET-PEP-01", "question_id": "ADMET-PEP-01", "pair_id": "ADMET-01", "category": "ADMET / Pharmacokinetic Properties", "domain": "peptide", "question_text": "What is the typical plasma half-life range for unmodified linear therapeutic peptides, and what are three primary strategies to extend it (include typical timescale changes)?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 20947, "timestamp": "2026-02-09T08:24:21.320218+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|ADMET-SM-07", "question_id": "ADMET-SM-07", "pair_id": "ADMET-07", "category": "ADMET / Pharmacokinetic Properties", "domain": "small_molecule", "question_text": "Assume hepatic blood flow Qh ≈ 90 L/h. A drug has hepatic clearance CLh = 60 L/h. Compute the extraction ratio E and state whether clearance is more likely flow-limited or capacity/fu-limited.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 15023, "timestamp": "2026-02-09T08:26:55.141718+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|ASSAY-SM-09", "question_id": "ASSAY-SM-09", "pair_id": "ASSAY-09", "category": "Assay Interpretation", "domain": "small_molecule", "question_text": "A PK/PD plot of effect vs plasma concentration shows counterclockwise hysteresis (effect lags concentration early and increases later at the same concentration). What does this imply about system dynamics, and what sampling strategy improves model identifiability?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 45668, "timestamp": "2026-02-09T08:30:34.966782+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|ASSAY-SM-01", "question_id": "ASSAY-SM-01", "pair_id": "ASSAY-01", "category": "Assay Interpretation", "domain": "small_molecule", "question_text": "Define IC50 in a biochemical inhibition assay and state one key assay-condition factor that can shift the measured IC50 without changing true binding affinity.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **IC50** (half-maximal inhibitory concentration) is the concentration of an inhibitor that reduces the activity of a target enzyme (or receptor) by 50% under specific experimental conditions. It is an operational measure of apparent potency, distinct from the intrinsic binding affinity (Ki).\n\n**Key assay-condition factor:** **Substrate concentration ([S])**.\n\nFor competitive inhibitors, the relationship is described by the Cheng-Prusoff equation:  \n**IC50 = Ki × (1 + [S]/Km)**\n\nIncreasing the substrate concentration increases the measured IC50 (making the inhibitor appear weaker), whereas decreasing [S] lowers the IC50 (making it appear more potent), even though the true dissociation constant (Ki) remains unchanged.", "latency_ms": 18619, "timestamp": "2026-02-09T08:30:56.586941+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|GEN-PEP-05", "question_id": "GEN-PEP-05", "pair_id": "GEN-05", "category": "Generative Design Strategies", "domain": "peptide", "question_text": "You condition a peptide generator to maximize predicted activity from an in silico model. What is a common failure mode, and what validation step reduces the risk of selecting ‘adversarial’ sequences?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " A common failure mode is **reward hacking (or model exploitation)**: the generator discovers sequences that maximize the in silico score by exploiting artifacts, biases, or spurious correlations in the specific predictive model (e.g., memorized training patterns, feature leakage, or physically implausible conformations that the scoring function mishandles), rather than genuine structure–activity relationships. These “adversarial” peptides often possess chemically unreasonable features (e.g., extreme hydrophobicity, repetitive motifs, or steric clashes) that trigger false-positive predictions.\n\nThe key validation step is **ensemble consensus scoring** (or model disagreement analysis). By evaluating generated candidates with multiple, diverse models (e.g., combining a physics-based docking score, a graph neural network, and a transformer-based affinity predictor) and filtering for sequences that rank highly across the ensemble (e.g., top 10% in ≥3 distinct architectures), you reduce the risk of selecting sequences that game a single predictor. Additional safeguards include **applicability domain (AD) filters** (", "latency_ms": 37058, "timestamp": "2026-02-09T08:31:36.646171+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|ASSAY-PEP-02", "question_id": "ASSAY-PEP-02", "pair_id": "ASSAY-02", "category": "Assay Interpretation", "domain": "peptide", "question_text": "A hemolysis assay for an antimicrobial peptide yields a steep dose–response with Hill slope ~3. Give a mechanistic interpretation consistent with peptide membrane-disruption behavior.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " A Hill slope of ~3 indicates strong positive cooperativity, consistent with a **multimeric pore-formation mechanism** requiring the cooperative assembly of approximately 3 peptide molecules to produce membrane disruption.\n\n**Mechanistic interpretation:**\n\n1.  **Oligomeric stoichiometry:** The value suggests that the lytic unit is likely a trimer or tetramer. In the **barrel-stave** or **toroidal pore** models, individual peptide monomers bind to the membrane surface and then undergo a cooperative insertion step where 3–4 peptides aggregate to form a stable, water-filled transmembrane pore. The steep sigmoidicity reflects the sharp transition that occurs once the local peptide concentration exceeds the threshold necessary for nucleation of these oligomeric pores.\n\n2.  **Positive cooperativity in membrane insertion:** Initial peptide binding may induce membrane thinning or curvature stress, increasing the affinity of the membrane for subsequent peptide molecules. This creates a \"snowball\" effect where binding facilitates further binding, generating the observed steep dose-response once a critical peptide-to-lipid ratio (~0.1–0.5 for many AMPs) is surpassed.\n\n3.  **Threshold phenomenon (Carpet model variant):** Even in non-pore carpet mechanisms, a Hill slope >1 can indicate that multiple peptides must simultaneously engage the outer leaflet to overcome the bilayer's elastic modulus and trigger micellization or catastrophic membrane failure.\n\n**Note:** While the Hill coefficient often approximates the number of ligand molecules required for activation, it reflects the **minimal functional oligomeric state** rather than precise stoichiometry. A slope of ~3 effectively rules out simple monomeric detergent-like action (nH ≈ 1) and strongly supports a cooperative, multi-hit mechanism for membrane permeabilization.", "latency_ms": 46904, "timestamp": "2026-02-09T08:32:26.550888+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|ADMET-SM-04", "question_id": "ADMET-SM-04", "pair_id": "ADMET-04", "category": "ADMET / Pharmacokinetic Properties", "domain": "small_molecule", "question_text": "A small molecule has systemic clearance CL = 30 L/h and volume of distribution Vd = 300 L in humans. Estimate the terminal half-life and interpret what a Vd this large typically implies about tissue distribution.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **Terminal half-life:**  \nUsing \\( t_{1/2} = \\frac{0.693 \\times V_d}{CL} \\):\n\n\\[\nt_{1/2} = \\frac{0.693 \\times 300\\ \\text{L}}{30\\ \\text{L/h}} \\approx \\mathbf{6.9\\ \\text{hours}}\\ (\\text{or roughly } \\mathbf{7\\ \\text{h}})\n\\]\n\n**Interpretation of \\( V_d = 300\\ \\text{L} \\):**  \nThis value is **~7–8× total body water** (~40–42 L in a 70 kg adult) and indicates **extensive tissue distribution**. It implies the drug is highly lipophilic or binds avidly to tissue proteins/phospholipids (e.g., in adipose, muscle, or organ parenchyma), such that only a small fraction of the total drug in the body remains in plasma at equilibrium. Consequently, plasma concentrations will be low relative to the total amount of drug present systemically.", "latency_ms": 28831, "timestamp": "2026-02-09T08:32:58.383066+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|ASSAY-PEP-04", "question_id": "ASSAY-PEP-04", "pair_id": "ASSAY-04", "category": "Assay Interpretation", "domain": "peptide", "question_text": "A peptide is degraded by a protease with apparent first-order rate constant k = 0.023 min^-1 (measured under pseudo-first-order conditions). Compute the degradation half-life and interpret what this means for a 2-hour incubation assay.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **Half-life calculation**\n\nFor first-order kinetics:  \n$$t_{1/2} = \\frac{\\ln(2)}{k} = \\frac{0.693}{0.023\\ \\text{min}^{-1}} \\approx \\mathbf{30\\ \\text{minutes}}\\ (\\text{range: 30–31 min})$$\n\n**Interpretation for a 2‑hour (120‑min) assay**\n\n- **Duration relative to half‑life:** 120 min ÷ 30 min ≈ **4 half‑lives**.\n- **Remaining peptide:** Fraction remaining = $e^{-kt} = e^{-0.023 \\times 120} \\approx e^{-2.76} \\approx \\mathbf{6\\%}$ (range: 6–7 %).  \n  Thus, **~94 % of the peptide is degraded** by the end of the incubation.\n\n**Practical implications**\n\n1. **Substrate depletion:** If the peptide is a substrate for an enzymatic reaction, its concentration drops >90 % over the assay window, violating steady‑state assumptions and making initial‑rate determination unreliable unless the reaction is quenched much earlier (e.g., within one half‑life, ≤30 min).\n\n2. **Analytical stability:** If the peptide is the analyte being quantified, the signal decays exponentially; samples must be processed immediately or the protease inhibited to prevent ex vivo degradation.\n\n3. **Pharmacokinetic relevance:** A 30‑min half‑life suggests rapid systemic clearance (similar to many therapeutic peptides in plasma), implying limited exposure in vivo and a need for formulation or chemical stabilization (e.g., N‑methylation, cyclization, or D‑amino‑acid substitution) for drug development.", "latency_ms": 35482, "timestamp": "2026-02-09T08:33:36.866143+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|ADMET-PEP-07", "question_id": "ADMET-PEP-07", "pair_id": "ADMET-07", "category": "ADMET / Pharmacokinetic Properties", "domain": "peptide", "question_text": "Assume renal plasma flow Qr ≈ 45 L/h. A peptide has renal clearance CLr = 5 L/h. Compute extraction ratio E and state whether clearance is more likely flow-limited or capacity/fu-limited.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 22346, "timestamp": "2026-02-09T08:36:36.889207+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|SAR-SM-05", "question_id": "SAR-SM-05", "pair_id": "SAR-05", "category": "SAR Reasoning", "domain": "small_molecule", "question_text": "A ligand’s secondary amide NH donates a hydrogen bond to the target (N–O distance ~2.9 Å) and is critical for potency. What is the expected potency effect of replacing that amide with an ester at the same position, and what other property often changes in parallel?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 19796, "timestamp": "2026-02-09T08:39:22.320847+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|GEN-PEP-04", "question_id": "GEN-PEP-04", "pair_id": "GEN-04", "category": "Generative Design Strategies", "domain": "peptide", "question_text": "Phage display yields enrichment values across panning rounds. How can enrichment be used as a training signal for peptide sequence generation, and what experimental bias must be considered?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **Using Enrichment as a Training Signal**\n\nEnrichment values (typically calculated as the ratio of post-selection phage titer to input titer, or normalized sequence frequencies between rounds) serve as quantitative fitness proxies in machine learning pipelines:\n\n1.  **Regression Targets:** Enrichment ratios (often log-transformed, ranging from 0.1 to >1000× across 3–4 panning rounds) train supervised models (CNNs, Transformers, or RNNs) to predict binding potential from sequence. Models learn to map sequence space to continuous fitness landscapes.\n2.  **Generative Guidance:** In variational autoencoders (VAEs) or diffusion models, enrichment values weight the loss function or condition the latent space, steering generation toward high-fitness regions.\n3.  **Reinforcement Learning:** Enrichment provides the reward signal for policy gradient methods (e.g., REINFORCE), where the agent generates sequences and receives reward proportional to predicted or measured enrichment.\n4.  **Active Learning:** Enrichment uncertainties guide iterative library design, prioritizing sequences at the predicted fitness boundary for experimental validation.\n\n**Critical Experimental Biases**\n\nEnrichment is a composite signal conflating binding affinity with multiple confounding factors that must be explicitly modeled or experimentally controlled:\n\n*   **Amplification Bias:** During *E. coli* amplification between rounds (typically 10²–10⁴-fold expansion), sequence-dependent differences in phage replication rates (due to codon usage, toxicity of displayed peptides, or proteolytic degradation) can create 2–10× artificial enrichment unrelated to target binding.\n*   **Avidity vs. Affinity:** Multivalent display (3–5 copies of pIII fusion per virion) means enrichment often reflects avidity (apparent K_D in nM–μM range) rather than monoval", "latency_ms": 19684, "timestamp": "2026-02-09T08:39:45.005467+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|GEN-PEP-10", "question_id": "GEN-PEP-10", "pair_id": "GEN-10", "category": "Generative Design Strategies", "domain": "peptide", "question_text": "You expand a peptide generator to include several non-natural amino acids. What must be updated in the model representation and in downstream scoring to keep generation physically and chemically coherent?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " To incorporate non-natural amino acids (UAAs) into a peptide generative model while maintaining physical and chemical coherence, you must update both the **representation layer** and **scoring functions** as follows:\n\n## 1. Model Representation Updates\n\n**Vocabulary & Tokenization**\n- Expand the token dictionary to include new 3-letter codes (e.g., \"NLE\" for norleucine, \"BPA\" for *p*-benzoyl-L-phenylalanine) or SMILES/SELFIES substructures\n- Add stereochemistry flags (D- vs. L-configuration, R/S centers) to distinguish enantiomers\n\n**Feature Embeddings**\n- Initialize/train new embedding vectors for each UAA in the latent space\n- Update atomic feature vectors to include new elements (e.g., fluorine in trifluoromethyl-phenylalanine) or hybridization states (sp³ carbons in β-amino acids)\n- Extend graph neural network node features to account for novel side chain topologies (e.g., cyclic constraints in 1-aminocyclopentane-1-carboxylic acid)\n\n**Geometric Priors**\n- Update rotamer libraries (χ angle distributions)", "latency_ms": 24131, "timestamp": "2026-02-09T08:40:12.136943+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|OPT-PEP-02", "question_id": "OPT-PEP-02", "pair_id": "OPT-02", "category": "Optimization Approaches", "domain": "peptide", "question_text": "Define a Pareto-optimal set for peptides optimized simultaneously for higher potency, higher serum stability, and lower hemolysis. What does it mean for one peptide to dominate another?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " In multi-objective peptide optimization, the **Pareto-optimal set** (or Pareto front) is the collection of peptides for which **no single objective can be improved without worsening at least one other objective**. \n\nFor your three objectives—**maximizing potency", "latency_ms": 12898, "timestamp": "2026-02-09T08:40:55.475614+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|OPT-SM-08", "question_id": "OPT-SM-08", "pair_id": "OPT-08", "category": "Optimization Approaches", "domain": "small_molecule", "question_text": "In batch Bayesian optimization where you choose 20 compounds per cycle, why is within-batch diversity important, and name one method to enforce it during selection?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " Within-batch diversity is critical for three reasons:\n\n1. **Information efficiency**: Selecting 20 structurally similar compounds yields redundant data, wasting experimental resources that could explore distinct regions of chemical space. Diverse batches maximize information gain per cycle, accelerating model convergence.\n\n2. **Risk mitigation**: If a single scaffold has inherent liabilities (e.g., metabolic instability, toxicity), a homogeneous batch risks simultaneous failure of all", "latency_ms": 14891, "timestamp": "2026-02-09T08:41:43.828575+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|GEN-SM-03", "question_id": "GEN-SM-03", "pair_id": "GEN-03", "category": "Generative Design Strategies", "domain": "small_molecule", "question_text": "In fragment-based de novo design, why does starting from known fragments often improve hit rates, and what constraint is commonly applied to keep designs synthesizable?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " Starting from **known fragments** improves hit rates because these fragments have validated binding modes and established ligand efficiency (typically LE > 0.3 kcal/mol per heavy atom). They serve as \"anchors\" with proven complementarity to the target binding site, reducing the chemical search space from ~10^60 possible drug-like molecules to growable/linked subsets. Empirically, fragment-derived compounds show hit rates of **10–30%** in follow-up assays versus <1% for random HTS compounds.\n\nTo maintain synthesizability, designs are commonly constrained by **synthetic accessibility scores** (e.g., SAscore, SYBA, or SCScore) with thresholds typically **< 4.0–5.0** (on normalized scales), or more rigorously by **reaction-based enumeration**—allowing only bond formations corresponding to robust, known transformations (e.g., amide coupling, Suzuki-Miyaura, SNAr) and requiring that constituent fragments be **commercially available** (e.g., Enamine REAL database, >10^7 building blocks). Advanced systems apply **retrosynthetic analysis** (e.g., AiZynthFinder, CASP tools) to verify 1–3 step synthetic routes from stock reagents before scoring a design as valid.", "latency_ms": 34803, "timestamp": "2026-02-09T08:42:21.632444+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|ASSAY-SM-10", "question_id": "ASSAY-SM-10", "pair_id": "ASSAY-10", "category": "Assay Interpretation", "domain": "small_molecule", "question_text": "An HTS assay has positive-control mean signal μp = 10 with SD σp = 2, and negative-control mean μn = 100 with SD σn = 5. Compute Z' factor and interpret assay quality.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **Calculation:**\n\nThe Z′ factor is calculated as:\n\n$$Z' = 1 - \\frac{3\\sigma_p + 3\\sigma_n}{|\\mu_p - \\mu_n|}$$\n\nSubstituting the values:\n- $|\\mu_p - \\mu_n| = |10 - 100| = 90$\n- $3\\sigma_p + 3\\sigma_n = 3(2) + 3(5) = 6 + 15 = 21$\n\n$$Z' = 1 - \\frac{21}{90} = 1 - 0.233 = \\mathbf{0.77}$$\n\n(or exactly **0.767**)\n\n**Interpretation:**\n\nA Z′ factor of **0.77 indicates an excellent assay**. \n\nStandard interpretation thresholds:\n- **Z′ ≥ 0.5**: Excellent assay quality (large dynamic range, low variability)\n- **0 < Z′ < 0.5**: Marginal/poor separation (may work but with high false positive/negative rates)\n- **Z′ ≤ 0**: Unusable assay (controls overlap significantly)\n\nWith Z′ = 0.77, the assay shows robust separation between positive and negative controls (90-unit signal window) relative to the control variability, making it suitable for high-throughput screening.", "latency_ms": 29541, "timestamp": "2026-02-09T08:42:54.174232+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|GEN-SM-07", "question_id": "GEN-SM-07", "pair_id": "GEN-07", "category": "Generative Design Strategies", "domain": "small_molecule", "question_text": "Give three commonly used synthesizability/developability filters applied to generated small molecules and provide a typical numeric threshold for at least one of them.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 8310, "timestamp": "2026-02-09T08:45:33.950145+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|ASSAY-PEP-03", "question_id": "ASSAY-PEP-03", "pair_id": "ASSAY-03", "category": "Assay Interpretation", "domain": "peptide", "question_text": "An antimicrobial peptide has MIC = 2 µg/mL against a bacterium and hemolysis HC50 = 200 µg/mL. Compute the therapeutic index (HC50/MIC) and interpret it.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **Calculation:**\n\nTherapeutic Index (TI) = HC50 / MIC = 200 µg/mL ÷ 2 µg/mL = **100**\n\n**Interpretation:**\n\nA therapeutic index of **100** indicates that the antimicrobial peptide is **100-fold more potent** against the target bacterium than it is toxic to mammalian red blood cells (hemolysis). \n\n**Context:**\n- **TI > 10**: Generally considered minimally acceptable for antimicrobial peptide development\n- **TI = 100**: Represents **good selectivity** and a reasonable safety margin, suggesting the peptide can effectively inhibit bacterial growth at concentrations far below those causing host cell toxicity\n- **TI > 1000**: Considered excellent/selective\n\nWith a TI of 100, this peptide demonstrates promising drug-like properties with substantial separation between antimicrobial efficacy and hemolytic risk, though other toxicity parameters (e.g., cytotoxicity against nucleated mammalian cells, in vivo stability, immunogenicity) would need evaluation for complete safety profiling.", "latency_ms": 4785, "timestamp": "2026-02-09T08:45:41.736597+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|SAR-SM-07", "question_id": "SAR-SM-07", "pair_id": "SAR-07", "category": "SAR Reasoning", "domain": "small_molecule", "question_text": "A phenyl ring in a lead compound occupies a hydrophobic pocket in both the intended target and a close off-target homolog. Only the intended target has a nearby Ser OH positioned to hydrogen-bond to a ring heteroatom. What is the expected effect on target potency and selectivity of replacing phenyl with a 3-pyridyl ring (introducing one ring nitrogen), and why?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 7332, "timestamp": "2026-02-09T08:47:29.218415+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|ADMET-SM-09", "question_id": "ADMET-SM-09", "pair_id": "ADMET-09", "category": "ADMET / Pharmacokinetic Properties", "domain": "small_molecule", "question_text": "How do you experimentally distinguish reversible CYP inhibition from mechanism-based (time-dependent) inhibition in vitro, and why does time-dependent inhibition elevate clinical DDI risk?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **Experimental Distinction**\n\nThe standard approach is the **IC50 shift assay** with and without NADPH-dependent pre-incubation:\n\n1.  **Pre-incubation Protocol**: Incubate the test compound (7-10 concentrations) with human liver microsomes (HLM) or recombinant CYP enzyme **± NADPH** for **30–60 min** at 37°C. Then add probe substrate (e.g., midazolam for CYP3A4) + NADPH to measure residual enzyme activity.\n    *   **Reversible inhibition**: IC50 values remain constant regardless of pre-incubation time (fold-shift typically **<1.5**).\n    *   **Time-dependent inhibition (TDI)**: IC50 decreases (potency increases) with pre-incubation, yielding a **≥1.5-fold to 2-fold IC50 shift** (e.g., IC50 shifts from 10 µM with no pre", "latency_ms": 10321, "timestamp": "2026-02-09T08:48:02.773523+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|ADMET-PEP-02", "question_id": "ADMET-PEP-02", "pair_id": "ADMET-02", "category": "ADMET / Pharmacokinetic Properties", "domain": "peptide", "question_text": "A linear peptide is rapidly cleaved by trypsin-like proteases at a Lys site (cleavage after Lys). Name two peptide modifications that typically reduce this cleavage and explain why serum stability increases (include a typical qualitative timescale change).", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 11458, "timestamp": "2026-02-09T08:49:57.095934+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|ADMET-PEP-10", "question_id": "ADMET-PEP-10", "pair_id": "ADMET-10", "category": "ADMET / Pharmacokinetic Properties", "domain": "peptide", "question_text": "Why do small peptides (e.g., 1–5 kDa) often clear rapidly via the kidney, and how does increasing hydrodynamic size (e.g., PEGylation) reduce this clearance?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 9653, "timestamp": "2026-02-09T08:51:47.388201+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|GEN-SM-01", "question_id": "GEN-SM-01", "pair_id": "GEN-01", "category": "Generative Design Strategies", "domain": "small_molecule", "question_text": "In SMILES-based molecular generation, name three necessary validity conditions a generated string must satisfy to correspond to a chemically valid molecule.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 9148, "timestamp": "2026-02-09T08:53:39.609945+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|SAR-SM-10", "question_id": "SAR-SM-10", "pair_id": "SAR-10", "category": "SAR Reasoning", "domain": "small_molecule", "question_text": "A biaryl inhibitor rapidly interconverts between two atropisomers, but only one atropisomer fits the binding pocket. What design change is most likely to increase potency and selectivity, and why?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " The most effective design change is **introducing steric bulk (e.g., methyl, halogen, or isopropyl substituents) at the ortho-positions of the biaryl linkage** to raise the rotational energy barrier and \"lock\" the active atropisomer.\n\n**Why this increases potency:**\n- **Maximizes target engagement:** Rapid interconversion means only ~50% of molecules occupy the active atropisomer at equilibrium. Locking the configuration ensures 100% of the compound is competent for binding, effectively doubling the functional concentration.\n- **Reduces entropic penalty:** Pre-organizing the molecule into the bioactive conformation eliminates the conformational entropy cost (ΔS) paid upon binding, improving binding affinity (ΔG = ΔH - TΔS). A typical gain is **1-3 kcal/mol** in binding free energy, corresponding to **2- to 100-fold** increases in potency.\n\n**Why this increases selectivity:**\n- **Eliminates off-target binding:** The \"inactive\" atropisomer may bind promiscuously to other targets or allosteric sites. Locking prevents its existence, reducing off-target liability.\n- **Enables chiral discrimination:** Stabilizing the atropisomer (rotational barrier **>20–25 kcal/mol**) allows isolation of the single enantiomer (atropisomer), which often shows **>10–100-fold** selectivity over the antipode in cellular assays.\n\n**Key constraint:** The substituents must be large enough to prevent rotation (halting interconversion on the timescale of the assay/biological system) but not so large as to sterically clash with the binding pocket itself.", "latency_ms": 7369, "timestamp": "2026-02-09T08:55:26.618918+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|OPT-SM-04", "question_id": "OPT-SM-04", "pair_id": "OPT-04", "category": "Optimization Approaches", "domain": "small_molecule", "question_text": "In Bayesian optimization for molecules, what does Expected Improvement (EI) favor, and why is predictive uncertainty required for principled exploration?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " In Bayesian optimization (BO) for molecules, **Expected Improvement (EI) favors candidates with either high predicted property values (exploitation) or high predictive uncertainty (exploration)**, optimally balancing both via the acquisition function:\n\n$$\\text{EI}(x) = (\\mu(x) - f^*)\\Phi(Z) + \\sigma(x)\\phi(Z)$$\n\nwhere $\\mu(x)$ is the predicted mean, $\\sigma(x)$ is the predictive standard deviation, $f^*$ is the current best observed value, $Z = (\\mu(x) - f^*)/\\sigma(x)$, and $\\Phi/\\phi$ are the standard normal CDF/PDF.\n\n**Why predictive uncertainty is required for principled exploration:**\n\n1. **Automatic exploration-exploitation trade-off**: Without $\\sigma(x)$, the optimizer would greedily select molecules with highest predicted activity, ignoring whether those predictions are reliable. Uncertainty explicitly quantifies doubt, forcing exploration of chemical subspaces (e.g., novel scaffolds, unusual functional groups) where the surrogate model (often a Gaussian Process or neural network) lacks training data.\n\n2. **Avoiding spurious exploitation**: In vast chemical spaces ($\\sim10^{60}$ drug-like molecules), machine learning models confidently mispredict properties for out-of-distribution structures. Predictive uncertainty prevents the", "latency_ms": 124037, "timestamp": "2026-02-09T08:57:33.657036+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|OPT-PEP-01", "question_id": "OPT-PEP-01", "pair_id": "OPT-01", "category": "Optimization Approaches", "domain": "peptide", "question_text": "What is an alanine scan in peptide optimization, and what does a large activity loss upon Ala substitution at a position imply about that residue’s role?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " An **alanine scan** is a systematic mutagenesis strategy in which each amino acid residue in a peptide (or protein) is individually substituted with alanine to determine the contribution of specific side chains to biological activity (e.g., binding affinity, receptor activation, or enzymatic function). Alanine is chosen because its methyl side chain (–CH₃) is small, chemically inert, and removes all atoms beyond the Cβ carbon, thereby eliminating specific side-chain interactions (hydrogen bonding, electrostatic contacts, or hydrophobic packing) while minimally perturbing the backbone conformation.\n\n**Implication of large activity loss:**\nA significant decrease in activity (typically >5- to >100-fold loss in potency, depending on the assay) upon Ala substitution indicates that the original residue is a **\"hot spot\"** critical for function. Specifically, this implies:\n\n*   **Specific binding interactions:** The native side chain likely forms essential hydrogen bonds, salt bridges, or hydrophobic contacts with the target that cannot be accommodated by the small methyl group of alanine.\n*   **Steric or conformational constraints:** The residue may be required for maintaining the bioactive conformation through steric packing or restricting backbone flexibility; replacing it with the smaller alanine induces conformational disorder or collapse.\n*   **Functional specificity:** The loss is not merely due to bulk removal but to the loss of specific chemical functionality (e.g., a charged Lys or Glu, or an aromatic Tyr).\n\nConversely, retention of activity suggests the residue acts primarily as a structural spacer or is located in a non-critical region.", "latency_ms": 61064, "timestamp": "2026-02-09T08:58:37.722037+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|OPT-SM-01", "question_id": "OPT-SM-01", "pair_id": "OPT-01", "category": "Optimization Approaches", "domain": "small_molecule", "question_text": "What is matched molecular pair (MMP) analysis, and how is it used to prioritize substitutions during lead optimization?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **Matched Molecular Pair (MMP) analysis** is a cheminformatics method that identifies pairs of molecules differing by only a single, localized structural transformation (e.g., H → CH₃, Cl → F, or phenyl → pyridyl) at the same position, with identical \"context\" (surrounding scaffold). \n\n## Core Methodology\nAn MMP consists of two compounds (R-X and R-Y) sharing a common core (R) but differing at one attachment point (X vs. Y). Analysis involves mining historical databases (e.g., >10,000–100,000 compounds) to extract transformations and calculating the mean change (Δ) in biological or physicochemical properties:\n\n- **Activity shifts**: ΔpIC₅₀, ΔpEC₅₀  \n- **ADMET properties**: ΔlogP (typically +0.5 per added CH₂), ΔlogD, Δsolubility, ΔhERG IC₅₀, ΔCYP inhibition  \n- **Pharmacokinetics**: ΔCL, Δt½, ΔF (% bioavailability)\n\n## Prioritization in Lead Optimization\nMMP analysis prioritizes substitutions through **transformation rules** supported by statistical significance:\n\n1. **Quantitative Prediction**: If a transformation (e.g., *ortho*-Cl → *ortho*-CF₃ on a phenyl ring) historically yields ΔpIC₅₀ = +0.8 ± 0.3 log units across ≥3–5 distinct scaffolds (n≥3 is a common threshold for reliability), it is prioritized for synthesis over transformations with negligible or variable effects.\n\n2. **Activity Cliff Detection**: MMPs revealing large potency shifts (|ΔpIC₅₀| > 1.0) with minimal structural change flag \"hot spots\" for critical interactions, guiding focused SAR exploration.\n\n3. **Property Balancing**: Multiparameter optimization uses MMP \"swap rules\" to improve one property without degrading others. For example:\n   - Replacing a piperidine with a piperazine typically reduces logP by ~0.4–0.6 units while maintaining basicity\n   - Adding a para-F to an aniline often improves metabolic stability (reduces CYP2D6 inhibition by ~2–3-fold) with minimal steric impact\n\n4. **Context-Specific Guidance**: Analysis restricted to radius-1 or radius-2 environments (atoms 1–2 bonds from the attachment point) distinguishes scaffold-dependent effects from", "latency_ms": 39378, "timestamp": "2026-02-09T08:59:20.100751+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|SAR-PEP-04", "question_id": "SAR-PEP-04", "pair_id": "SAR-04", "category": "SAR Reasoning", "domain": "peptide", "question_text": "A peptide binds its target as an α-helix, and residue i is buried in a helix-dependent interface. What is the most likely effect on activity of substituting that residue from an L-amino acid to the corresponding D-amino acid, and why?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 103986, "timestamp": "2026-02-09T09:05:37.094599+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|ADMET-SM-08", "question_id": "ADMET-SM-08", "pair_id": "ADMET-08", "category": "ADMET / Pharmacokinetic Properties", "domain": "small_molecule", "question_text": "A basic drug has pKa = 9.5 and cLogP = 3.5. At intestinal pH 6.5, approximately what fraction is un-ionized, and what does that imply for passive permeability?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 53139, "timestamp": "2026-02-09T09:08:21.657800+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|ASSAY-PEP-10", "question_id": "ASSAY-PEP-10", "pair_id": "ASSAY-10", "category": "Assay Interpretation", "domain": "peptide", "question_text": "A peptide screening assay has positive-control mean μp = 20 with SD σp = 3, and negative-control mean μn = 100 with SD σn = 6. Compute Z' factor and interpret assay quality.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **Calculation**\n\nThe Z′ factor is calculated as:\n\n\\[\nZ' = 1 - \\frac{3\\sigma_p + 3\\sigma_n}{|\\mu_p - \\mu_n|}\n\\]\n\nSubstituting the values:\n- \\(|\\mu_p - \\mu_n| = |20 - 100| = 80\\)\n- \\(3\\sigma_p + 3\\sigma_n = 3(3) + 3(6) = 9 + 18 = 27\\)\n\n\\[\nZ' = 1 - \\frac{27}{80} = 1 - 0.3375 = \\mathbf{0.66}\n\\]\n\n**Interpretation**\n\nA Z′ factor of **0.66** indicates **excellent assay quality", "latency_ms": 144176, "timestamp": "2026-02-09T09:10:48.835018+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|GEN-SM-04", "question_id": "GEN-SM-04", "pair_id": "GEN-04", "category": "Generative Design Strategies", "domain": "small_molecule", "question_text": "What is reaction-aware molecular generation, and why does it typically produce a higher fraction of synthesizable proposals than unconstrained SMILES generation?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **Reaction-aware molecular generation** is a computational approach that designs molecules by explicitly simulating chemical reactions—either by assembling building blocks through valid synthetic transformations or by optimizing structures within the constraints of known reaction mechanisms and available starting materials. Unlike string-based methods, it treats synthesis as an integral part of the generative process, often using reaction templates (e.g., from databases like USPTO or Reaxys), forward-reaction prediction models, or retrosynthetic constraints.\n\n**Why it produces higher fractions of synthesizable proposals:**\n\n1. **Construction from validated synthons**  \n   These methods assemble molecules from commercially available or pre-validated building blocks (e.g., boronic acids, amines, aldehydes) using robust, well-characterized reactions (e.g., Suzuki–Miyaura couplings, amide bond formations). This ensures the product inherently possesses a retrosynthetic disconnections strategy, whereas unconstrained SMILES generation creates structures *de novo* without regard to starting materials or bond-forming feasibility.\n\n2. **Enforcement of chemical grammar**  \n   Unconstrained SMILES generators (e.g., char-RNNs or GPT models) produce 5–20% syntactically invalid strings and a significant fraction of chemically unstable or impossible structures (e.g., pentavalent carbons, unrealistic ring strain). Reaction-aware generation maintains valence rules and reaction mechanisms by construction, typically achieving >95% chemical validity and ensuring ring systems and functional groups are compatible with real synthetic chemistry.\n\n3. **Implicit optimization of synthetic accessibility**  \n   By restricting the chemical space to", "latency_ms": 52263, "timestamp": "2026-02-09T09:11:54.876343+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|SAR-SM-02", "question_id": "SAR-SM-02", "pair_id": "SAR-02", "category": "SAR Reasoning", "domain": "small_molecule", "question_text": "A carboxylate on a small molecule forms a salt bridge to a Lys side chain (N–O distance ~2.8–3.0 Å) and is required for activity. What is the most likely effect on potency if you convert the carboxylic acid to a methyl ester, and why?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **Most likely effect:** A substantial decrease in potency (typically **10- to >100-fold**, potentially abolishing activity).\n\n**Reasoning:**\n\n1.  **Loss of the salt bridge:** At physiological pH, the Lys side chain is protonated (–NH₃⁺, pKa ~10.5) and the carboxylic acid is deprotonated (–COO⁻, pKa ~4–5). The 2.8–3.0 Å N–O distance indicates a strong, charge-assisted hydrogen bond (salt bridge) contributing approximately **1–3 kcal/mol** (up to", "latency_ms": 40298, "timestamp": "2026-02-09T09:12:38.174853+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|GEN-PEP-06", "question_id": "GEN-PEP-06", "pair_id": "GEN-06", "category": "Generative Design Strategies", "domain": "peptide", "question_text": "Name two generation-time techniques that increase diversity of generated peptide sequences and one quantitative diversity metric commonly used for sequences.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 47073, "timestamp": "2026-02-09T09:18:11.397069+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|SAR-SM-09", "question_id": "SAR-SM-09", "pair_id": "SAR-09", "category": "SAR Reasoning", "domain": "small_molecule", "question_text": "A tertiary amine (pKa ~9) forms a salt bridge to an Asp in the binding site (N–O distance ~2.8 Å). You replace the tertiary amine with an amide at the same position. What is the most likely potency effect and why?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 118698, "timestamp": "2026-02-09T09:25:56.325637+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|ADMET-SM-10", "question_id": "ADMET-SM-10", "pair_id": "ADMET-10", "category": "ADMET / Pharmacokinetic Properties", "domain": "small_molecule", "question_text": "What approximate molecular-weight threshold is commonly associated with increased biliary excretion for small molecules, and what other physicochemical features favor biliary vs renal elimination?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 850, "timestamp": "2026-02-09T09:30:29.728611+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|GEN-SM-10", "question_id": "GEN-SM-10", "pair_id": "GEN-10", "category": "Generative Design Strategies", "domain": "small_molecule", "question_text": "You expand a molecular generator to include non-standard charged fragments (new tokens not seen in the original training set). What two components must be updated to keep generation chemically consistent and valid?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 67272, "timestamp": "2026-02-09T09:36:45.861753+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|OPT-SM-05", "question_id": "OPT-SM-05", "pair_id": "OPT-05", "category": "Optimization Approaches", "domain": "small_molecule", "question_text": "A lead compound is cleared rapidly due to oxidative N-dealkylation of a tertiary amine. Propose two structural changes that often reduce this clearance while preserving a basic center, and explain why they work.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 67439, "timestamp": "2026-02-09T09:42:11.123196+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|ADMET-SM-02", "question_id": "ADMET-SM-02", "pair_id": "ADMET-02", "category": "ADMET / Pharmacokinetic Properties", "domain": "small_molecule", "question_text": "A benzylic CH2 is identified as the major CYP oxidation soft spot (rapid benzylic hydroxylation). Name one structural change that typically reduces this metabolism and explain the mechanism (include a typical magnitude of intrinsic clearance reduction).", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 76294, "timestamp": "2026-02-09T09:48:49.740047+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|OPT-SM-02", "question_id": "OPT-SM-02", "pair_id": "OPT-02", "category": "Optimization Approaches", "domain": "small_molecule", "question_text": "In multi-parameter optimization (MPO) for small molecules, how does a weighted desirability function combine objectives, and what is the limitation when objectives conflict?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " In multi-parameter optimization (MPO), weighted desirability functions combine objectives by first scaling each property (e.g., potency, logP, solubility) to a common 0–1 scale using individual desirability functions (*d*ᵢ), where 0 = unacceptable and 1 = ideal. These are aggregated using a weighted geometric mean:\n\n**D = (Π *d*ᵢ^wᵢ)^(1/Σwᵢ)**\n\nwhere *w*ᵢ represents the relative importance of parameter *i*. The overall desirability *D* (0–1) enables compound ranking.\n\n**Limitation with conflicting objectives:**\nThe primary limitation is **compensation masking**: high desirability in one objective can mathematically compensate for unacceptable performance in another, potentially selecting compounds that violate critical constraints. For example, with equal weights (*w* = 1), a compound with excellent potency (*d* = 1.0) but poor aqueous sol", "latency_ms": 101100, "timestamp": "2026-02-09T09:50:33.840654+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|ADMET-SM-03", "question_id": "ADMET-SM-03", "pair_id": "ADMET-03", "category": "ADMET / Pharmacokinetic Properties", "domain": "small_molecule", "question_text": "What physicochemical profile is commonly associated with hERG liability, and what in vitro hERG IC50 threshold is often treated as a significant flag for follow-up?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **Physicochemical Profile Associated with hERG Liability**\n\nhERG blockers typically share a \"pharmacophore\" consisting of a **protonatable basic nitrogen** (pKₐ usually **> 7.5–8.0**) flanked by **lipophilic/hydrophobic groups** (often aromatic rings). Key physicochemical flags include:\n\n*   **Basicity:** A centrally located basic amine (often tertiary) that is positively charged at physiological pH.\n*   **High lipophil", "latency_ms": 21678, "timestamp": "2026-02-09T09:52:15.948578+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|SAR-PEP-03", "question_id": "SAR-PEP-03", "pair_id": "SAR-03", "category": "SAR Reasoning", "domain": "peptide", "question_text": "A linear 10-mer peptide binds a target in a compact turn-like conformation. What is the most likely effect of head-to-tail cyclization on potency and why (assume cyclization does not directly block a key contact residue)?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 34696, "timestamp": "2026-02-09T09:55:38.503643+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|SAR-SM-04", "question_id": "SAR-SM-04", "pair_id": "SAR-04", "category": "SAR Reasoning", "domain": "small_molecule", "question_text": "A chiral secondary alcohol is positioned so that only the (S)-enantiomer can donate a hydrogen bond to an Asp residue; the (R)-enantiomer points the substituent into a tight hydrophobic cleft causing steric clash. Which enantiomer is expected to be more potent, and what magnitude of potency difference is commonly observed in such cases?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 47245, "timestamp": "2026-02-09T09:59:36.082918+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|OPT-PEP-04", "question_id": "OPT-PEP-04", "pair_id": "OPT-04", "category": "Optimization Approaches", "domain": "peptide", "question_text": "How can Bayesian optimization be applied to peptide sequences using embeddings, and what does EI do in that setting?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " Bayesian optimization (BO) can be applied to peptide sequences by mapping discrete sequences into a continuous **embedding space** where standard BO operates, then using acquisition functions like Expected Improvement (EI) to guide the search. Here is the specific workflow and role of EI:\n\n## 1. Embedding Peptides for BO\nSince peptides are discrete (sequences of 20 amino acids) and often variable-length, they are first encoded into fixed-dimensional continuous vectors (embeddings, **z** ∈ ℝᵈ, typically **d = 64–1024**):\n\n- **Learned embeddings**: Variational autoencoders (VAEs) or protein language models (e.g., ESM-2, ProtBERT) trained on sequence databases map peptides to latent vectors that capture physicochemical and structural properties.\n- **Hand-crafted embeddings**: Physicochemical descriptors (hydrophobicity, charge, molecular weight) concatenated into feature vectors.\n\nThe BO surrogate model—typically a **Gaussian Process (GP)**—is then trained on the dataset **D = {(zᵢ, yᵢ)}**, where **zᵢ** is the embedding of peptide **i** and **yᵢ** is the experimental property (e.g., binding affinity, IC₅₀, stability).\n\n## 2. Optimization", "latency_ms": 64887, "timestamp": "2026-02-09T10:00:43.970640+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|ASSAY-SM-02", "question_id": "ASSAY-SM-02", "pair_id": "ASSAY-02", "category": "Assay Interpretation", "domain": "small_molecule", "question_text": "A dose–response curve fit yields a Hill slope of 0.5 (much shallower than 1). Give two mechanistic interpretations relevant to small-molecule assays.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 27244, "timestamp": "2026-02-09T10:04:53.322149+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|SAR-PEP-10", "question_id": "SAR-PEP-10", "pair_id": "SAR-10", "category": "SAR Reasoning", "domain": "peptide", "question_text": "A peptide bond adjacent to a Pro residue exists as a cis/trans mixture in solution, but only the trans conformer binds the target. What modification is most likely to increase apparent potency, and why?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 30091, "timestamp": "2026-02-09T10:08:28.549182+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|OPT-PEP-10", "question_id": "OPT-PEP-10", "pair_id": "OPT-10", "category": "Optimization Approaches", "domain": "peptide", "question_text": "You have four peptides with (EC50 nM, serum half-life h, hemolysis HC50 µg/mL): A(10, 0.2, 50), B(30, 8, 40), C(15, 2, 200), D(50, 20, 20). Objectives: minimize EC50, maximize half-life, maximize HC50. Which peptides are Pareto-optimal?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 31944, "timestamp": "2026-02-09T10:11:18.741497+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|GEN-PEP-02", "question_id": "GEN-PEP-02", "pair_id": "GEN-02", "category": "Generative Design Strategies", "domain": "peptide", "question_text": "Protein language models trained with a masked-token objective can be used for peptide ‘inpainting’. What does the masked-token objective learn, and why does it enable filling variable positions around a fixed motif?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " The **masked-token objective** trains the model to predict randomly masked amino-acid tokens from their surrounding sequence context. Formally, it learns the conditional probability distribution **P(x<sub>i</sub> | x<sub>\\i</sub>)**—the likelihood of an amino acid at position *i* given all other (unmasked) positions.\n\n**What it learns:**\n*   **Contextual dependencies:** Local sequence constraints (e.g., steric hindrance, secondary structure propensities) and long-range co-evolutionary couplings (e.g., contacts that stabilize tertiary structure).\n*   **Physicochemical compatibility:** Implicit rules governing charge, hydrophobicity, and size distributions that maintain protein stability and solubility.\n*   **Evolutionary fitness:** Tolerance patterns for substitutions, effectively approximating the underlying fitness landscape of natural protein families.\n\n**Why this enables inpainting:**\nInpainting exploits the fact that the model was trained to fill “holes” (masked positions) conditioned on visible context", "latency_ms": 45060, "timestamp": "2026-02-09T10:12:06.802350+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|ASSAY-SM-06", "question_id": "ASSAY-SM-06", "pair_id": "ASSAY-06", "category": "Assay Interpretation", "domain": "small_molecule", "question_text": "A compound has target IC50 = 200 nM and cellular CC50 (viability) = 20 µM. Compute the in vitro safety window (CC50/IC50) and state one follow-up assay you would run to contextualize the cytotoxicity.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **Safety window:** 100-fold (or 100×)\n\n**Calculation:**  \nCC50 (20 µM) ÷ IC50 (200 nM = 0.2 µM) = **100**\n\n**Follow-up assay:**  \nRun a **cytotoxicity assay in an isogenic target-knockout (KO) cell line** (or a target-negative parental line). If the CC50 shifts significantly (e.g., ≥5-fold increase) in the absence of the target, the cytotoxicity is likely **on-target** (mechanism-related); if unchanged, it suggests **off-target** toxicity. \n\n*Alternative acceptable answers:* Caspase-3/7 activation assay (to distinguish apoptosis from necrosis), or testing in relevant primary human cells to assess therapeutic index versus transformed cell lines.", "latency_ms": 42053, "timestamp": "2026-02-09T10:13:59.058171+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|ADMET-SM-01", "question_id": "ADMET-SM-01", "pair_id": "ADMET-01", "category": "ADMET / Pharmacokinetic Properties", "domain": "small_molecule", "question_text": "State Lipinski’s Rule-of-Five thresholds (MW, cLogP, HBD, HBA) and give two mechanistic reasons why violating multiple thresholds tends to reduce oral exposure.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 40338, "timestamp": "2026-02-09T10:18:07.855815+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|SAR-SM-01", "question_id": "SAR-SM-01", "pair_id": "SAR-01", "category": "SAR Reasoning", "domain": "small_molecule", "question_text": "A ligand’s para-substituent on a phenyl ring points into a hydrophobic subpocket and sits ~3.2 Å from a protein backbone carbonyl oxygen (geometry compatible with a halogen bond). If the para-methyl analog has IC50 = 200 nM, what is the most likely potency change when replacing para-CH3 with para-Cl, and what is the mechanistic rationale?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 40060, "timestamp": "2026-02-09T10:21:44.743912+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|ASSAY-PEP-08", "question_id": "ASSAY-PEP-08", "pair_id": "ASSAY-08", "category": "Assay Interpretation", "domain": "peptide", "question_text": "In an in vivo antibacterial study, increasing peptide dose increases plasma exposure linearly but bacterial load reduction plateaus at ~60% and does not improve further. What does this suggest mechanistically, and what is one follow-up measurement to confirm?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 48917, "timestamp": "2026-02-09T10:26:02.512965+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|GEN-PEP-09", "question_id": "GEN-PEP-09", "pair_id": "GEN-09", "category": "Generative Design Strategies", "domain": "peptide", "question_text": "List four quantitative metrics commonly used to evaluate peptide sequence generative models and briefly state what each measures.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " 1.  **Perplexity** – Measures the model’s predictive performance by quantifying how well it estimates the probability distribution of the next amino acid in a sequence (lower values indicate better calibration and sequence learning).\n\n2.  **Validity** – The percentage of generated sequences that are chemically legitimate (e.g., contain only standard 20 amino‑acid residues, satisfy length constraints, and lack invalid tokens or stop codons).\n\n3.  **Novelty** – The proportion of generated sequences that are not exact matches (or have <100% identity) to any sequence in the training set, assessing the degree of memorization versus *de novo* generation.\n\n4.  **", "latency_ms": 34458, "timestamp": "2026-02-09T10:28:31.230843+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|ASSAY-PEP-07", "question_id": "ASSAY-PEP-07", "pair_id": "ASSAY-07", "category": "Assay Interpretation", "domain": "peptide", "question_text": "Three peptide variants have (EC50 nM, serum stability t1/2 min): A(30, 15), B(80, 240), C(20, 5). If you require EC50 ≤ 50 nM and serum t1/2 ≥ 60 min for the next round, which variant best meets criteria and what is the most logical next step?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 40085, "timestamp": "2026-02-09T10:31:57.518404+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|GEN-PEP-07", "question_id": "GEN-PEP-07", "pair_id": "GEN-07", "category": "Generative Design Strategies", "domain": "peptide", "question_text": "Give three developability/manufacturability filters applied to generated peptide sequences and provide a typical numeric threshold for at least one (e.g., charge or length).", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 24337, "timestamp": "2026-02-09T10:35:17.629946+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|ASSAY-PEP-05", "question_id": "ASSAY-PEP-05", "pair_id": "ASSAY-05", "category": "Assay Interpretation", "domain": "peptide", "question_text": "In a mouse efficacy study of a therapeutic peptide dosed weekly, efficacy improves on days 1–3 but wanes by week 3 despite unchanged dosing. Give two plausible assay-linked explanations and name one measurement that distinguishes them.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 83122, "timestamp": "2026-02-09T10:40:44.897188+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|ADMET-PEP-03", "question_id": "ADMET-PEP-03", "pair_id": "ADMET-03", "category": "ADMET / Pharmacokinetic Properties", "domain": "peptide", "question_text": "Name three common drivers of peptide immunogenicity (anti-drug antibody risk) and two mitigation strategies used in therapeutic peptide design.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 57082, "timestamp": "2026-02-09T10:45:06.939687+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|OPT-PEP-06", "question_id": "OPT-PEP-06", "pair_id": "OPT-06", "category": "Optimization Approaches", "domain": "peptide", "question_text": "A peptide binds both a target receptor and a homolog. Only the target has a unique Asp near the interface; the homolog has Asn at that position. What sequence modification strategy is most likely to improve selectivity, and why?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 93932, "timestamp": "2026-02-09T10:51:36.703460+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|ASSAY-SM-03", "question_id": "ASSAY-SM-03", "pair_id": "ASSAY-03", "category": "Assay Interpretation", "domain": "small_molecule", "question_text": "A compound has IC50 = 50 nM on the intended target and IC50 = 5 µM on an off-target. Compute the selectivity ratio and interpret whether this is generally considered strong selectivity.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **Selectivity ratio:** **100-fold** (or 100×)\n\n**Calculation:**  \n5 µM = 5,000 nM  \nSelectivity = IC₅₀(off-target) / IC₅₀(on-target) = 5,000 nM / 50 nM = **100**\n\n**Interpretation:**  \nThis is generally considered **moderate to good selectivity**, meeting the minimum acceptable threshold (typically ≥100-fold) for many drug discovery programs. However, it is not exceptional:\n\n*   **<10-fold:** Poor (likely unacceptable)\n*   **10–100-fold:** Moderate (may be acceptable depending on the off-target risk)\n*   **>100-fold:** Good/selective\n*   **>1,000-fold:** Excellent/highly selective (often required for critical safety targets like hERG or major CYP isoforms)\n\nA 100-fold window provides a reasonable safety margin, though many programs aim for **≥1,000-fold** selectivity against high-risk off-targets to ensure robust therapeutic indices in vivo.", "latency_ms": 76679, "timestamp": "2026-02-09T10:52:56.383887+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|OPT-PEP-09", "question_id": "OPT-PEP-09", "pair_id": "OPT-09", "category": "Optimization Approaches", "domain": "peptide", "question_text": "A baseline peptide has Kd = 1.0 µM. Mutation A gives Kd = 0.30 µM, mutation B gives Kd = 0.20 µM, and double mutant AB gives Kd = 0.020 µM. Under a multiplicative (log-additive) model, what Kd would you predict for AB, and does the result indicate synergy?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 25801, "timestamp": "2026-02-09T10:56:41.902142+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|OPT-SM-03", "question_id": "OPT-SM-03", "pair_id": "OPT-03", "category": "Optimization Approaches", "domain": "small_molecule", "question_text": "In a QSAR-guided lead-optimization loop, what minimum experimental data characteristics are needed to retrain reliably and reduce overfitting risk?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 43204, "timestamp": "2026-02-09T11:00:29.388533+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|ADMET-PEP-05", "question_id": "ADMET-PEP-05", "pair_id": "ADMET-05", "category": "ADMET / Pharmacokinetic Properties", "domain": "peptide", "question_text": "A peptide’s renal filtration is approximately proportional to its free (unbound) fraction. If lipidation increases albumin binding and reduces fu from 0.5 to 0.01 (50-fold), what qualitative change do you expect in renal clearance and half-life (assume Vd is roughly unchanged)?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **Renal clearance** would decrease by approximately **50-fold** (proportional to the reduction in free fraction), and **half-life** would increase by approximately **50-fold**.\n\n**Rationale:**\n- Glomerular filtration is restricted to unbound drug, so renal clearance (CLᵣ", "latency_ms": 41347, "timestamp": "2026-02-09T11:01:13.736796+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|ADMET-PEP-04", "question_id": "ADMET-PEP-04", "pair_id": "ADMET-04", "category": "ADMET / Pharmacokinetic Properties", "domain": "peptide", "question_text": "A therapeutic peptide has systemic clearance CL = 12 L/h and Vd = 4 L in humans. Estimate the terminal half-life and interpret what a Vd near 3–5 L typically implies about distribution.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **Terminal half-life calculation:**\n\nUsing the relationship \\( t_{1/2} = \\frac{0.693 \\times V_d}{CL} \\):\n\n\\[ t_{1/2} = \\frac{0.693 \\times 4\\ \\text{L}}{12\\ \\text{L/h}} = \\frac{2.772}{12} \\approx \\mathbf{0.23\\ \\text{hours}}\\ (\\approx \\mathbf{14\\ \\text{minutes}}) \\]\n\n**Interpretation of Vd ≈ 3–5 L:**\n\nA volume of distribution in the 3–5 L range approximates the **plasma volume (~3 L) or total blood volume (~5 L)** in an average adult. This indicates:\n\n1. **Limited tissue distribution**: The peptide remains largely confined to the vascular (central) compartment with minimal penetration into peripheral tissues or cells\n2. **Hydrophilic character**: Consistent with peptides that cannot readily cross lipid membranes to access intracellular spaces or adipose tissue\n3. **Potential constraints**: May reflect high plasma protein binding, rapid renal filtration, or exclusion from the ~12 L of interstitial fluid due to size/charge\n\nFor context: Extracellular fluid Vd ≈ 15 L, total body water ≈ 40 L, while extensively distributed drugs can have Vd > 100 L.", "latency_ms": 60072, "timestamp": "2026-02-09T11:02:16.809417+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|ASSAY-SM-05", "question_id": "ASSAY-SM-05", "pair_id": "ASSAY-05", "category": "Assay Interpretation", "domain": "small_molecule", "question_text": "A compound’s apparent IC50 shifts from 1.0 µM with 5-minute preincubation to 50 nM with 60-minute preincubation. What mechanism does this suggest, and what follow-up assay distinguishes covalent from slow-tight binding?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " The 20‑fold increase in potency (1.0 µM → 50 nM) with prolonged preincubation indicates **time‑dependent inhibition**, most consistent with either **slow‑tight binding** (slow onset, high‑affinity reversible binding) or **covalent/irreversible** inhibition.\n\n**Follow‑up assay to distinguish the two:**  \nA **jump‑dilution (reversibility) assay**:\n1. Preincubate the enzyme with the inhibitor (e.g., at 10 × IC₅₀) for 60 min to allow full binding.  \n2. Dilute the mixture 100‑fold into assay buffer containing saturating substrate.  \n3. Monitor enzymatic activity over time (e.g., 30–120 min).\n\n- **Covalent inhibitor:** No recovery of activity (remains >90 % inhibited) because dilution cannot reverse a chemical bond.  \n- **Slow‑tight binder:** Slow, exponential recovery of activity as the inhibitor dissociates (rate governed by *k*ₒff), typically reaching 50–100 % activity within minutes to hours depending on the residence time.\n\n**Alternative confirmation:** Mass spectrometry (detecting a mass shift corresponding to the inhibitor adduct) or dialysis/gel‑filtration followed by activity assay (irreversible inhibitors remain bound after buffer exchange; reversible inhibitors dissociate).", "latency_ms": 33091, "timestamp": "2026-02-09T11:02:52.900793+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|ASSAY-PEP-09", "question_id": "ASSAY-PEP-09", "pair_id": "ASSAY-09", "category": "Assay Interpretation", "domain": "peptide", "question_text": "Protease degradation of a peptide shows biphasic kinetics: 60% loss in the first 10 minutes, then slow decay over the next 2 hours. Give one kinetic explanation and one experiment that tests it.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 52410, "timestamp": "2026-02-09T11:07:26.831835+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|SAR-SM-03", "question_id": "SAR-SM-03", "pair_id": "SAR-03", "category": "SAR Reasoning", "domain": "small_molecule", "question_text": "A ligand has a flexible linker (6 rotatable bonds) between two pharmacophoric groups. A co-crystal shows the bound conformation is U-shaped, but in solution the ligand is highly flexible. What is the most likely effect of macrocyclizing the linker to bias the U-shape, and why?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " The most likely effect is **increased binding affinity**, typically improving potency by **10- to 100-fold** (ΔΔG ≈ **1.4–2.8 kcal/mol** at 298 K), assuming the macrocycle does not introduce severe strain.\n\n**Reasoning:**\n\n1.  **Reduced Entropic Penalty:** The flexible linker", "latency_ms": 44433, "timestamp": "2026-02-09T11:09:57.140779+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|GEN-SM-08", "question_id": "GEN-SM-08", "pair_id": "GEN-08", "category": "Generative Design Strategies", "domain": "small_molecule", "question_text": "You have a 3D pharmacophore with two H-bond acceptors ~7 Å apart and one hydrophobic feature. How can a generative model be conditioned to satisfy this, and what quantitative post-generation check verifies success?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **Conditioning Strategies**\n\n1. **Pharmacophore-Distance Matrix Conditioning**  \n   Encode the 3D pharmacophore as a pairwise distance matrix (e.g., HBA₁–HBA₂ = 7 Å, HBA–hydrophobe = *d", "latency_ms": 52016, "timestamp": "2026-02-09T11:11:46.029295+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|OPT-PEP-08", "question_id": "OPT-PEP-08", "pair_id": "OPT-08", "category": "Optimization Approaches", "domain": "peptide", "question_text": "In designing an affinity-maturation library for a peptide, why do you typically limit the number of mutated positions per variant, and how does this relate to epistasis and library size?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " In affinity maturation, you typically limit randomized positions to **2–4 residues per variant** (and rarely exceed 6) due to the constraints of **combinatorial explosion** and **epistatic interactions**.\n\n## Library Size Constraints\nThe theoretical diversity of a library randomizing *N* positions with 20 amino acids (e.g., NNK codons) is **20^N**. Practical display technologies have finite capacities:\n- **Phage", "latency_ms": 38898, "timestamp": "2026-02-09T11:12:27.928179+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|SAR-PEP-06", "question_id": "SAR-PEP-06", "pair_id": "SAR-06", "category": "SAR Reasoning", "domain": "peptide", "question_text": "A stapled α-helical peptide binds a protein–protein interaction target, and CD measurements show ~60% helicity in solution. What is the most likely activity effect of removing the staple (keeping the same sequence otherwise), and why?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **Most likely effect:** A **10- to 100-fold decrease in binding affinity** (and corresponding cellular activity), with the unstapled peptide dropping to **<20%", "latency_ms": 39422, "timestamp": "2026-02-09T11:14:03.246874+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|OPT-PEP-05", "question_id": "OPT-PEP-05", "pair_id": "OPT-05", "category": "Optimization Approaches", "domain": "peptide", "question_text": "A peptide lead clears rapidly primarily via renal filtration and proteolysis. Name two half-life extension strategies and explain which clearance component each mainly addresses.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 27665, "timestamp": "2026-02-09T11:18:12.161853+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|ASSAY-SM-04", "question_id": "ASSAY-SM-04", "pair_id": "ASSAY-04", "category": "Assay Interpretation", "domain": "small_molecule", "question_text": "A competitive inhibitor has IC50 = 100 nM in an assay run at substrate concentration [S] = 50 µM. The enzyme’s Km for substrate is 10 µM. Using Cheng–Prusoff, estimate Ki.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " Using the Cheng–Prusoff equation for competitive inhibition:\n\n**Ki = IC50 / (1 + [S]/Km)**\n\nPlugging in the values:\n*   [S]/Km = 50 µM / 10 µM = **5**\n*   Ki = 100 nM / (1 + 5) = 100 nM / **6**\n\n**Ki ≈ 16.7 nM** (or approximately **17 nM**)\n\nThus, the true binding affinity of the inhibitor is roughly 6-fold tighter than the apparent IC50 measured under these assay conditions.", "latency_ms": 14403, "timestamp": "2026-02-09T11:18:29.565462+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|SAR-PEP-07", "question_id": "SAR-PEP-07", "pair_id": "SAR-07", "category": "SAR Reasoning", "domain": "peptide", "question_text": "A peptide binds both a target protein and a close homolog. Only the target has a Tyr OH positioned to hydrogen-bond with a side-chain acceptor at the interface. What is the expected effect on potency and selectivity of substituting a Val at the interface to an Asn (introducing a side-chain carbonyl acceptor), and why?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 61767, "timestamp": "2026-02-09T11:22:28.892656+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|SAR-PEP-09", "question_id": "SAR-PEP-09", "pair_id": "SAR-09", "category": "SAR Reasoning", "domain": "peptide", "question_text": "A peptide’s Lys side chain forms a salt bridge to an Asp on the target protein (N–O distance ~2.8 Å). You mutate Lys to Gln at that position. What is the most likely effect on binding/activity and why?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **", "latency_ms": 43381, "timestamp": "2026-02-09T11:23:15.274347+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|ADMET-SM-05", "question_id": "ADMET-SM-05", "pair_id": "ADMET-05", "category": "ADMET / Pharmacokinetic Properties", "domain": "small_molecule", "question_text": "A highly metabolized drug has high intrinsic clearance (CLint >> hepatic blood flow). Using the well-stirred model, how does decreasing the unbound fraction in plasma from fu = 0.01 to fu = 0.005 tend to change hepatic clearance, and why?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 44165, "timestamp": "2026-02-09T11:26:56.474254+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|ADMET-PEP-06", "question_id": "ADMET-PEP-06", "pair_id": "ADMET-06", "category": "ADMET / Pharmacokinetic Properties", "domain": "peptide", "question_text": "A 12-mer peptide has net charge +3 and many hydrogen-bond donors (backbone + side chains), giving poor cell permeability. Name two chemical strategies that can increase cell permeability while keeping the same amino-acid sequence identity largely intact, and explain why they work.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 33727, "timestamp": "2026-02-09T11:30:13.958302+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|ADMET-PEP-08", "question_id": "ADMET-PEP-08", "pair_id": "ADMET-08", "category": "ADMET / Pharmacokinetic Properties", "domain": "peptide", "question_text": "Some cyclic peptides (~1000–1200 Da) can show measurable oral exposure despite violating Rule-of-Five guidelines. Name three molecular features that enable this and explain the mechanism in terms of effective polarity.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 46804, "timestamp": "2026-02-09T11:34:36.215657+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|ASSAY-SM-08", "question_id": "ASSAY-SM-08", "pair_id": "ASSAY-08", "category": "Assay Interpretation", "domain": "small_molecule", "question_text": "A compound tested as a receptor agonist reaches only 60% of the maximal response produced by a known full agonist, even at saturating concentrations. What does this imply about the compound’s pharmacology, and how should EC50 be interpreted?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " This compound is a **partial agonist** with an **intrinsic efficacy** approximately 60% that of the full agonist (assuming the full agonist defines ε = 1.0).\n\n**Pharmacological Implications:**\n\n*   **Ceiling Effect:** The compound produces a submaximal response (60% Emax) even when 100% of receptors are occupied. It cannot elicit the full biological response regardless of concentration.\n*   **Functional Antagonism:** In the presence of a full agonist, this compound will competitively inhibit the full agonist's response while producing its own 60% effect. At high concentrations, it can reduce the full agonist's 100% response down to its own 60% ceiling (a net antagonism of 40%).\n*   **Spare Receptors:** Unlike full agonists, partial agonists generally cannot leverage spare receptors to achieve maximal tissue response.\n\n**EC50 Interpretation:**\n\nThe **EC50 remains a measure of potency (affinity)**, not efficacy. It is defined as the concentration producing **50% of the partial agonist's own maximal response** (i.e., the concentration yielding 30% of the full agonist's maximal effect).\n\n*   **Critical distinction:** EC50 does **not** indicate the concentration needed to reach 50% of the full agonist's response. It indicates the concentration needed to reach 30% of the full agonist's response (half of 60%).\n*   EC50 is independent of intrinsic efficacy; a partial agonist can have higher or lower affinity (lower or", "latency_ms": 46919, "timestamp": "2026-02-09T11:35:26.135911+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|SAR-PEP-02", "question_id": "SAR-PEP-02", "pair_id": "SAR-02", "category": "SAR Reasoning", "domain": "peptide", "question_text": "A peptide’s Asp side chain forms a salt bridge to a Lys on the target protein (distance ~2.8–3.0 Å) and is required for activity. What is the most likely effect on potency if Asp is substituted with Asn at that position, and why?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **Significant decrease in potency** (typically 10- to 100-fold or greater increase in IC₅₀/Kd).\n\n**Reasoning:**\nThe Asp→Asn substitution replaces a negatively charged carboxylate (–COO⁻) with a neutral carboxamide (–CONH₂). This eliminates the **salt bridge** (ionic interaction) with the target Lys (ε-NH₃⁺), which contributes approximately **3–5 kcal/mol** to binding affinity in a low-dielectric environment (e.g., a buried interface). \n\nWhile Asn can form hydrogen", "latency_ms": 34670, "timestamp": "2026-02-09T11:36:58.896108+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|SAR-SM-08", "question_id": "SAR-SM-08", "pair_id": "SAR-08", "category": "SAR Reasoning", "domain": "small_molecule", "question_text": "A lead compound binds in a folded conformation. You add a gem-dimethyl group adjacent to the folding hinge (Thorpe–Ingold effect) to bias the folded conformation. If conformational preorganization improves binding free energy by ~1.0 kcal/mol, approximately what potency change (fold) would you expect at 298 K, and why?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 33610, "timestamp": "2026-02-09T11:40:38.768074+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|ASSAY-PEP-01", "question_id": "ASSAY-PEP-01", "pair_id": "ASSAY-01", "category": "Assay Interpretation", "domain": "peptide", "question_text": "Define MIC for an antimicrobial peptide and describe the typical dilution scheme used to measure it (include the standard concentration step size).", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **Minimum Inhibitory Concentration (MIC)** for an antimicrobial peptide (AMP) is defined as the lowest concentration of the peptide that inhibits visible growth of a specific microorganism (typically 10⁵–10⁶ CFU/mL) after a standardized incubation period (usually 16–24 hours at 35–37°C).\n\n**Typical Dilution Scheme:**\nThe standard method follows CLSI (M07) or ISO 20776-1 broth microdilution guidelines using 96-well microtiter plates:\n\n*   **Step size:** **2-fold (geometric) serial dilutions** (each concentration is 50% of the preceding one)\n*   **Concentration range:** Typically **128 µg/mL to 0.25 µg/mL** (or 0.5 µg/mL), though AMPs may require higher starting concentrations (up to 512 µg/mL) due to aggregation or reduced potency compared to conventional antibiotics\n*   **Format:** 100 µL peptide solution per well in cation-adjusted Mueller-Hinton broth (MHB), with final inoculum of ~5 × 10⁵ CFU/mL\n*   **Controls:** Growth control (no peptide), sterility control (no bacteria), and solvent control if peptides are dissolved in DMSO/acetic acid\n\n**AMP-Specific Considerations:** Due to AMPs' propensity for adsorption to polystyrene and aggregation at high concentrations, low-binding plates or supplemented media (e.g., 0.2% BSA or 0.01% Tween-20) are sometimes used to minimize surface binding, though these modifications must be reported as they can shift MIC values.", "latency_ms": 25640, "timestamp": "2026-02-09T11:41:07.408897+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|GEN-PEP-01", "question_id": "GEN-PEP-01", "pair_id": "GEN-01", "category": "Generative Design Strategies", "domain": "peptide", "question_text": "In sequence-based peptide generation, what makes a generated peptide sequence syntactically valid, and what additional constraint is often imposed for therapeutic developability?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 11306, "timestamp": "2026-02-10T00:24:28.316968+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|SAR-PEP-01", "question_id": "SAR-PEP-01", "pair_id": "SAR-01", "category": "SAR Reasoning", "domain": "peptide", "question_text": "A peptide ligand has a Leu side chain that inserts into a hydrophobic subpocket adjacent to an aromatic residue that can support edge-to-face π interactions. If the Leu-containing peptide has Kd = 200 nM, what is the most likely binding change when substituting that Leu with Phe, and why?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 12928, "timestamp": "2026-02-10T00:26:27.796863+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|SAR-PEP-08", "question_id": "SAR-PEP-08", "pair_id": "SAR-08", "category": "SAR Reasoning", "domain": "peptide", "question_text": "A peptide binds as an α-helix but is mostly disordered in solution. Stapling increases preorganization and improves binding free energy by ~1.0 kcal/mol. Approximately what fold-improvement in affinity would you expect at 298 K, and what is the mechanism?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 17941, "timestamp": "2026-02-10T00:28:44.763679+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|GEN-PEP-01", "question_id": "GEN-PEP-01", "pair_id": "GEN-01", "category": "Generative Design Strategies", "domain": "peptide", "question_text": "In sequence-based peptide generation, what makes a generated peptide sequence syntactically valid, and what additional constraint is often imposed for therapeutic developability?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 27678, "timestamp": "2026-02-10T01:45:05.286725+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|SAR-PEP-01", "question_id": "SAR-PEP-01", "pair_id": "SAR-01", "category": "SAR Reasoning", "domain": "peptide", "question_text": "A peptide ligand has a Leu side chain that inserts into a hydrophobic subpocket adjacent to an aromatic residue that can support edge-to-face π interactions. If the Leu-containing peptide has Kd = 200 nM, what is the most likely binding change when substituting that Leu with Phe, and why?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 30022, "timestamp": "2026-02-10T01:47:46.784079+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|SAR-PEP-08", "question_id": "SAR-PEP-08", "pair_id": "SAR-08", "category": "SAR Reasoning", "domain": "peptide", "question_text": "A peptide binds as an α-helix but is mostly disordered in solution. Stapling increases preorganization and improves binding free energy by ~1.0 kcal/mol. Approximately what fold-improvement in affinity would you expect at 298 K, and what is the mechanism?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": "", "latency_ms": 11382, "timestamp": "2026-02-10T01:50:38.438323+00:00", "success": false, "error": "ValueError: Empty response content from model"}
{"response_id": "kimi-k2.5:cloud|GEN-PEP-01", "question_id": "GEN-PEP-01", "pair_id": "GEN-01", "category": "Generative Design Strategies", "domain": "peptide", "question_text": "In sequence-based peptide generation, what makes a generated peptide sequence syntactically valid, and what additional constraint is often imposed for therapeutic developability?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " ## Syntactic Validity in Sequence-Based Peptide Generation\n\nA generated peptide sequence is **syntactically valid** when it consists exclusively of the 20 standard proteinogenic amino acids (or specified non-canonical residues) encoded by single-letter or three-letter codes, forming a continuous chain without invalid characters, premature stop codons, or chemically implausible linkages.\n\n## Therapeutic Developability Constraint\n\nThe critical additional constraint is **drug-like physicochemical property filtering**, most commonly:\n\n- **Molecular weight**: typically <500–1000 Da (oral peptides) or <3–5 kDa (parenteral)\n- **Hydrophobicity**: logP or GRAVY score within ranges minimizing aggregation/poor solubility\n- **Charge balance**: net charge typically −2 to +2 at physiological pH\n- **Specific structural liabilities**: absence of N-terminal Gln/Asn (pyroglutamate formation), Pro-Gly motifs (cis-trans isomerization), or Cys-rich sequences (disulfide scrambling)\n\n**Example**: Therapeutic peptide libraries often enforce Lipinski-like rules adapted for peptides (e.g., ≤30 amino acids, ≤5 positive charges) and exclude sequences predicted to have >10% aggregation propensity by tools like TANGO or Aggrescan.", "latency_ms": 5459, "timestamp": "2026-02-10T01:51:04.118009+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|SAR-PEP-01", "question_id": "SAR-PEP-01", "pair_id": "SAR-01", "category": "SAR Reasoning", "domain": "peptide", "question_text": "A peptide ligand has a Leu side chain that inserts into a hydrophobic subpocket adjacent to an aromatic residue that can support edge-to-face π interactions. If the Leu-containing peptide has Kd = 200 nM, what is the most likely binding change when substituting that Leu with Phe, and why?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " ## Most Likely Outcome: Improved Binding (Kd ~20-50 nM, ~4-10× tighter)\n\n### Reasoning\n\n**Structural complementarity enhancement:**\n- Leu provides **aliphatic hydrophobic contact** (ΔG ≈ -0.5 to -1.0 kcal/mol from the side chain)\n- Phe retains this **hydrophobic contribution** (similar buried surface area: Leu ~120 Å² vs. Phe ~145 Å²) **plus** adds **π-π edge-to-face interaction** with the adjacent aromatic residue\n\n**The π-π contribution:**\n- Edge-to-face (T-shaped) interactions typically contribute **-0.5 to -1.5 kcal/mol**\n- Combined with optimized shape complementarity in the subpocket\n\n**Calculated effect:**\n- ΔΔG ≈ -0.8 to -1.4 kcal/mol from added π interaction\n- Corresponds to **4-10× improvement** in Kd (200 nM → **20-50 nM**)\n\n### Caveats\n\n| Factor | Potential Impact |\n|--------|---------------|\n| Steric clash if subpocket shallow | Could abolish binding |\n| Alternative Phe rotamer | May not align for π-π contact |\n| Desolvation penalty | Phe has higher ΔG_desolv (~1.5 vs. 0.5 kcal/mol) |\n\nIf the subpocket depth accommodates Phe's bulk without strain, **tighter binding is expected**.", "latency_ms": 3621, "timestamp": "2026-02-10T01:51:10.740076+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|SAR-PEP-08", "question_id": "SAR-PEP-08", "pair_id": "SAR-08", "category": "SAR Reasoning", "domain": "peptide", "question_text": "A peptide binds as an α-helix but is mostly disordered in solution. Stapling increases preorganization and improves binding free energy by ~1.0 kcal/mol. Approximately what fold-improvement in affinity would you expect at 298 K, and what is the mechanism?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " At 298 K, a ~1.0 kcal/mol improvement in binding free energy (ΔΔG) corresponds to approximately a **5- to 6-fold improvement in affinity** (using ΔΔG = -RT ln(K_d,mut/K_d,wt), where RT ≈ 0.59 kcal/mol).\n\n## Mechanism\n\nThe affinity gain comes from **reduced conformational entropy penalty upon binding** (the \"preorganization\" effect):\n\n- In solution, the disordered peptide explores many conformations, only a small fraction of which are α-helical and binding-competent\n- Stapling (typically via an all-hydrocarbon crosslink between i and i+4 residues) locks the peptide into a helical conformation\n- This decreases the **entropic cost of folding** upon binding (ΔS_bind is less negative)\n- The ~1.0 kcal/mol figure is consistent with estimates that restricting a single rotatable bond contributes ~0.5–1.0 kcal/mol; a staple restricts multiple backbone φ/ψ angles\n\nNotably, this is primarily an **enthalpy-entropy compensation** effect rather than new binding contacts—the staple itself often makes minimal direct interactions with the target.", "latency_ms": 6814, "timestamp": "2026-02-10T01:51:20.554671+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|OPT-SM-10", "question_id": "OPT-SM-10", "pair_id": "OPT-10", "category": "Optimization Approaches", "domain": "small_molecule", "question_text": "You have four compounds with (IC50 nM, solubility µM, clearance mL/min/kg): A(10, 5, 40), B(30, 50, 20), C(15, 10, 10), D(50, 200, 60). Objectives: minimize IC50 and clearance, maximize solubility. Which compounds are Pareto-optimal?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " I need to find Pareto-optimal compounds where no other compound is better in all three objectives (minimize IC50, minimize clearance, maximize solubility).\n\nLet me compare each compound against others:\n\n| Compound | IC50 (nM) | Solubility (µM) | Clearance (mL/min/kg) |\n|----------|-----------|-----------------|----------------------|\n| A | 10 | 5 | 40 |\n| B | 30 | 50 | 20 |\n| C | 15 | 10 | 10 |\n| D | 50 | 200 | 60 |\n\n**Checking dominance:**\n\n- **A vs B**: A has better IC50 (10<30), but worse solubility (5<50) and worse clearance (40>20) → **non-dominated**\n- **A vs C**: A has better IC50 (10<15), but worse solubility (5<10) and worse clearance (40>10) → **non-dominated**\n- **A vs D**: A has better IC50 (10<50), worse solubility (5<200), better clearance (40<60) → **non-dominated**\n\n- **B vs A**: B has worse IC50, better solubility, better clearance → **non-dominated**\n- **B vs C**: B has worse IC50 (30>15), better solubility (50>10), worse clearance (20>10) → **non-dominated**\n- **B vs D**: B has better IC50 (30<50), worse solubility (50<200), better clearance (20<60) → **non-dominated**\n\n- **C vs A**: C has worse IC50, better solubility, better clearance → **non-dominated**\n- **C vs B**: C has better IC50 (15<30), worse solubility (10<50), better clearance (10<20) → **non-dominated**\n- **C vs D**: C has better IC50 (15<50), worse solubility (10<200), better clearance (10<60) → **non-dominated**\n\n- **D vs A**: D has worse IC50, better solubility, worse clearance → **dominated by A** (A beats D in IC50 and clearance; D only wins in solubility)\n- **D vs B**: D has worse IC50, better solubility, worse clearance → **dominated by B** (B beats D in IC50 and clearance)\n- **D vs C**: D has worse IC50, better solubility, worse clearance → **dominated by C** (C beats D in IC50 and clearance)\n\n**D is dominated** (A, B, and C all beat it in 2 of 3 criteria while losing only in solubility).\n\n**Pareto-optimal compounds: A, B, and C**\n\nNo compound among A, B, C dominates another—each represents a different trade-off:\n- **A**: Best potency (10 nM), worst solubility and clearance\n- **B**: Best solubility (50 µM) among optimal set, moderate potency and clearance\n- **C**: Best clearance (10 mL/min/kg), balanced potency and solubility", "latency_ms": 7330, "timestamp": "2026-02-10T01:51:30.885243+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|OPT-PEP-07", "question_id": "OPT-PEP-07", "pair_id": "OPT-07", "category": "Optimization Approaches", "domain": "peptide", "question_text": "Cyclization improves a peptide’s protease stability but reduces affinity because the ring distorts the bioactive geometry. What optimization lever can restore affinity while keeping most of the stability gain, and why?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **Optimization lever: Conformational constraint through strategic cyclization point selection or incorporation of rigidifying elements**\n\n**Why this works:**\n\n- **Strategic cyclization points**: Moving the cyclization position to preserve, rather than disrupt, the bioactive conformation. For example, cyclizing through residues not involved in the binding interface (e.g., N- and C-termini vs. side chains) can stabilize the overall fold while leaving the pharmacophore unstrained. Macrocycle ring size optimization (typically 12–20 atoms for peptide macrocycles) balances rigidity with sufficient flexibility to adopt the bound conformation.\n\n- **Rigidifying elements**: Incorporating non-proteogenic amino acids (e.g., α,α-disubstituted amino acids, N-alkylated residues, or proline analogs) at non-binding positions restricts backbone flexibility without distorting the active site. These \"staples\" reduce the entropic penalty of binding by pre-organizing the peptide into a binding-competent conformation.\n\n- **SAR-guided refinement**: Systematic N-methylation scanning (typically 10–30% of backbone amides) can identify positions where modification improves both metabolic stability *and* affinity by stabilizing specific secondary structures (e.g., β-turns, α-helices) recognized by the target.\n\nThe key principle: **conformational pre-organization** reduces the entropic cost of binding (ΔG ≈ −TΔS gain of 2–5 kcal/mol for constrained peptides) while protease resistance derives from the cyclic topology blocking exopeptidase access and reducing endopeptidase susceptibility—two benefits that are not mutually exclusive when the constraint is placed judiciously.", "latency_ms": 5543, "timestamp": "2026-02-10T01:51:39.429514+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|GEN-PEP-08", "question_id": "GEN-PEP-08", "pair_id": "GEN-08", "category": "Generative Design Strategies", "domain": "peptide", "question_text": "In structure-conditioned peptide design for a binding groove, what is typically held fixed vs optimized (backbone vs side chains), and what quantitative structural metric can verify that the designed peptide matches the intended fold?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " In structure-conditioned peptide design for binding grooves:\n\n**Typically Fixed:**\n- **Backbone conformation** (dihedral angles φ, ψ, and often ω), maintaining the target secondary structure (α-helix, β-strand, or extended loop)\n\n**Typically Optimized:**\n- **Side chain identities and rotamers** (χ angles), to achieve complementary shape, hydrogen bonding, and electrostatics with the groove surface\n\n**Quantitative Verification Metric:**\n- **Backbone RMSD** (root-mean-square deviation) to the intended fold, typically **<1–2 Å** for designed vs. target backbone coordinates; more stringently, **<0.5–1.0 Å** for core binding residues\n- **Cα RMSD** or **heavy-atom RMSD** of the peptide backbone are standard benchmarks in design validation (e.g., in Rosetta or AlphaFold-based workflows)\n\nAlternative/additional metrics: **TM-score** (>0.5 indicates same fold), **GDT-TS**, or **backbone dihedral angle RMSD** (e.g., <15–20° for φ/ψ).", "latency_ms": 3539, "timestamp": "2026-02-10T01:51:45.968885+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|OPT-SM-07", "question_id": "OPT-SM-07", "pair_id": "OPT-07", "category": "Optimization Approaches", "domain": "small_molecule", "question_text": "Adding a fluorine to block a metabolic soft spot increases cLogP from 2.5 to 3.5. What developability risk commonly increases as cLogP rises by ~1 unit, and name one mitigation approach that does not remove the fluorine.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **Risk:** **Increased risk of poor aqueous solubility and/or higher plasma protein binding**, both of which can reduce free drug concentration and compromise pharmacokinetic exposure.\n\nWith cLogP rising from 2.5 to 3.5, the molecule crosses into the \"high lipophilicity\" zone (cLogP >3 is often flagged in developability assessments). This typically correlates with:\n- Lower kinetic/thermodynamic solubility\n- Higher fraction bound to plasma proteins (often >95% for cLogP >4, with measurable increases beginning in the 3–4 range)\n\n**Mitigation approach (retaining the fluorine):**\n- **Introduce a polar, non-ionizable solubilizing group** at a distal, metabolically stable position—e.g., a primary amide, urea, or sulfone—to increase polar surface area (PSA) and improve aqueous solubility without compromising metabolic blockade by the fluorine. Target PSA increase of ~20–40 Å², which often partially offsets lipophilicity-driven solubility loss.", "latency_ms": 4788, "timestamp": "2026-02-10T01:51:53.757969+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|GEN-PEP-03", "question_id": "GEN-PEP-03", "pair_id": "GEN-03", "category": "Generative Design Strategies", "domain": "peptide", "question_text": "A peptide binder design strategy fixes a short epitope (e.g., 4 residues) and generates sequences by varying flanking positions. Why can this improve success rates, and what constraint is commonly applied to keep candidates developable?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " This strategy improves success rates through two key mechanisms:\n\n**Why it works:**\n- **Epitope validation** — The fixed 4-residue segment is pre-validated for target binding (e.g., from phage display, co-crystal structures, or known ligands), ensuring a functional anchor\n- **Focused sampling** — Varying only flanking positions (typically 2–4 residues per side) reduces sequence space from astronomical (20^N) to tractable (20^4–20^8 for 8–12 total residues), enabling exhaustive or ML-guided exploration\n- **Affinity maturation** — Flanking residues optimize secondary interactions (electrostatics, hydrophobic packing, backbone H-bonds) without disrupting the core epitope's geometry\n\n**Common developability constraint:**\n- **Molecular weight ceiling: 500–1000 Da** (ideally <500 Da for oral bioavailability, or <1000 Da for injectable peptides)\n- This typically restricts total length to **8–15 residues**, with the fixed epitope representing 25–50% of the sequence\n\nAdditional constraints often include: net charge −2 to +2 at pH 7.4, ≤2 consecutive hydrophobic residues to prevent aggregation, and exclusion of oxidation-prone residues (Cys, Met) unless structurally required.", "latency_ms": 3525, "timestamp": "2026-02-10T01:52:00.283427+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|GEN-SM-05", "question_id": "GEN-SM-05", "pair_id": "GEN-05", "category": "Generative Design Strategies", "domain": "small_molecule", "question_text": "You condition a generator to maximize a QSAR-predicted property (e.g., potency) using classifier guidance. What is a common failure mode of this approach, and what is one practical way to detect it?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " ## Common Failure Mode: **Mode Collapse to \"ADMET-Failed\" Molecules**\n\nThe generator often collapses to structures that exploit QSAR model artifacts—producing molecules with inflated predicted potency that are actually **synthetically intractable, chemically unstable, or possess poor ADMET properties** (e.g., extreme lipophilicity, reactive functional groups, or Pan-Assay Interference Compounds/PAINs features).\n\nThis occurs because:\n- QSAR models are trained on limited chemical space with correlated features (e.g., potency vs. logP)\n- Classifier guidance amplifies spurious correlations (e.g., adding hydrophobic groups to boost predicted binding without real selectivity)\n- The generator finds \"adversarial\" structures that maximize prediction scores without genuine biological activity\n\n---\n\n## Practical Detection Method: **Property Distribution Shift Monitoring**\n\nTrack the **Jensen-Shannon divergence (JSD)** or **Kolmogorov-Smirnov statistic** between generated molecules and training set distributions for **physicochemical properties** (MW, logP, TPSA, HBD/HBA counts, QED).\n\n| Threshold | Interpretation |\n|-----------|---------------|\n| JSD > 0.2–0.3 for ≥2 properties | Significant distribution shift; likely mode collapse |\n| Median logP shift > 1.5 units | Lipophilicity exploitation detected |\n| % QED < 0.3 increases >5× | Drug-likeness collapse |\n\n**Implementation:** Run generation with guidance scale λ; if property distributions diverge monotonically with increasing λ, the guidance is driving toward non-drug-like space rather than genuine potency optimization.\n\n---\n\n*Alternative detection: Retrospective docking or FEP+ on top-ranked generated molecules—if predicted binding scores poorly correlate with QSAR potency, the model is likely hallucinating.*", "latency_ms": 8066, "timestamp": "2026-02-10T01:52:11.350155+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|ASSAY-SM-07", "question_id": "ASSAY-SM-07", "pair_id": "ASSAY-07", "category": "Assay Interpretation", "domain": "small_molecule", "question_text": "Three analogs have (IC50 nM, kinetic solubility µM): A(30, 2), B(80, 50), C(20, 0.5). If you require IC50 ≤ 50 nM and solubility ≥ 5 µM for the next round, which analog best meets criteria and what is the most logical next experimental step?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **Best analog: A**\n\n| Analog | IC50 (nM) | Solubility (µM) | Meets IC50 ≤50? | Meets solubility ≥5? | Passes both? |\n|--------|-----------|-----------------|-----------------|----------------------|--------------|\n| A | 30 | 2 | ✓ Yes | ✗ No | No |\n| B | 80 | 50 | ✗ No | ✓ Yes | No |\n| C | 20 | 0.5 | ✓ Yes | ✗ No | No |\n\nNone fully meet both criteria. **A is closest** — it misses solubility by only 3 µM (needs 2.5× improvement), whereas B misses potency by 1.6× and C misses solubility by 10×.\n\n**Most logical next step:** Optimize **A** by modest structural modifications to improve solubility (e.g., introducing polar groups, reducing lipophilicity, or exploring salt forms) while monitoring that IC50 remains ≤50 nM.", "latency_ms": 2225, "timestamp": "2026-02-10T01:52:16.576623+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|ADMET-PEP-09", "question_id": "ADMET-PEP-09", "pair_id": "ADMET-09", "category": "ADMET / Pharmacokinetic Properties", "domain": "peptide", "question_text": "In an in vivo PK study, a peptide shows accelerating clearance over repeated weekly dosing despite similar initial exposure. What two mechanisms can cause this, and what measurements distinguish them?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " Two mechanisms can cause accelerating clearance with repeated weekly peptide dosing:\n\n## 1. **Anti-Drug Antibody (ADA) Formation**\n\n**Mechanism:** Immunogenicity generates neutralizing or non-neutralizing antibodies that enhance clearance through immune complex formation and FcRn-independent elimination.\n\n**Distinguishing measurements:**\n- ADA titers (screening and confirmatory assays)\n- Neutralizing antibody (NAb) assays\n- Immune complex detection\n- Often shows **non-linear, unpredictable** clearance acceleration\n\n---\n\n## 2. **Target-Mediated Drug Disposition (TMDD) with Target Accumulation**\n\n**Mechanism:** Repeated dosing saturates then upregulates target expression, or target accumulates (e.g., shed receptor, soluble target), creating a \"sink\" that expands with each dose.\n\n**Distinguishing measurements:**\n- **Total target levels** (free + bound) increasing in serum/tissue\n- Free drug vs. total drug PK divergence\n- Target occupancy saturation followed by increased capacity\n- Often shows **dose-dependent, saturable** kinetics that normalize at higher doses\n\n---\n\n**Key discriminator:** TMDD typically improves with dose escalation (saturable), while ADA-driven clearance worsens or persists regardless of dose.", "latency_ms": 7159, "timestamp": "2026-02-10T01:52:26.736577+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|ADMET-SM-06", "question_id": "ADMET-SM-06", "pair_id": "ADMET-06", "category": "ADMET / Pharmacokinetic Properties", "domain": "small_molecule", "question_text": "A candidate has TPSA = 140 Å², HBD = 3, and is a P-gp substrate. Name two design strategies that can increase oral absorption and briefly explain the mechanism.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " Two design strategies to increase oral absorption for this candidate:\n\n## 1. **Reduce TPSA to <90–100 Å²**\n- **Mechanism:** High TPSA (140 Å²) limits passive transcellular diffusion across lipid bilayers. Lowering TPSA improves membrane permeability by reducing desolvation penalties and increasing lipophilicity. The \"rule of 5\" suggests TPSA >140 Å² correlates with poor absorption, and even moderate reduction toward 90–100 Å² can significantly enhance permeability.\n\n## 2. **Reduce HBD count to ≤2**\n- **Mechanism:** Each HBD (particularly –OH and –NH) forms hydrogen bonds with water that must be broken for membrane partitioning. With 3 HBDs, the candidate exceeds Lipinski's recommended limit (≤5, but ≤2 is better for permeability). Removing or masking one HBD (e.g., via methylation, esterification, or bioisosteric replacement) reduces the energy barrier for membrane entry.\n\n**Note on P-gp:** While these changes address passive permeability, addressing P-gp efflux would require additional strategies (e.g., structural modifications to reduce P-gp recognition, or co-administration with P-gp inhibitors).", "latency_ms": 9647, "timestamp": "2026-02-10T01:52:39.383975+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|ADMET-PEP-01", "question_id": "ADMET-PEP-01", "pair_id": "ADMET-01", "category": "ADMET / Pharmacokinetic Properties", "domain": "peptide", "question_text": "What is the typical plasma half-life range for unmodified linear therapeutic peptides, and what are three primary strategies to extend it (include typical timescale changes)?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " ## Typical Plasma Half-Life\n\nUnmodified linear therapeutic peptides generally have very short plasma half-lives, typically **5–30 minutes**, with many falling in the **10–20 minute range**. This rapid clearance results from proteolytic degradation and renal filtration (cutoff ~30–50 kDa; peptides <10 kDa are rapidly filtered).\n\n---\n\n## Three Primary Extension Strategies\n\n| Strategy | Mechanism | Typical Half-Life Extension |\n|----------|-----------|----------------------------|\n| **PEGylation** | Conjugation to polyethylene glycol (PEG) increases hydrodynamic radius, reducing renal clearance and shielding from proteases | **10–100×** (hours to days; e.g., PEG-interferon: ~40 hr vs. native ~4 hr) |\n| **Fc fusion** | Fusion to IgG Fc domain enables neonatal Fc receptor (FcRn) recycling, extending circulation | **100–1000×** (days; e.g., etanercept: ~4.8 days; native TNF receptor: minutes) |\n| **Lipidation/Albumin binding** | Conjugation to fatty acids (e.g., palmitic, stearic acid) or albumin-binding moieties promotes reversible albumin association | **10–200×** (hours to ~1–2 days; e.g., insulin detemir: ~5–7 hr vs. regular insulin ~0.5–1 hr; semaglutide: ~1 week with C18 di-acid + linker optimization) |\n\n---\n\n## Additional Notes\n\n- **Cyclization** (e.g., disulfide or head-to-tail) and **D-amino acid substitution** can improve protease stability but typically provide more modest extensions (~2–10×) unless combined with other approaches.\n- The **FcRn recycling mechanism** (pH-dependent binding at endosomal pH 6.0, release at pH 7.4) is particularly efficient for long-acting biologics.", "latency_ms": 8330, "timestamp": "2026-02-10T01:52:50.714391+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|ADMET-SM-07", "question_id": "ADMET-SM-07", "pair_id": "ADMET-07", "category": "ADMET / Pharmacokinetic Properties", "domain": "small_molecule", "question_text": "Assume hepatic blood flow Qh ≈ 90 L/h. A drug has hepatic clearance CLh = 60 L/h. Compute the extraction ratio E and state whether clearance is more likely flow-limited or capacity/fu-limited.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " ## Calculation\n\n**Extraction ratio (E):**\n$$E = \\frac{CL_h}{Q_h} = \\frac{60}{90} = 0.67 \\text{ (or 67%)}$$\n\n## Classification\n\nWith **E = 0.67**, this drug has **intermediate-to-high extraction**.\n\n## Likely Limiting Factor\n\nGiven **E > 0.5**, hepatic clearance is **more likely flow-limited**.\n\n### Reasoning:\n- **Flow-limited drugs**: E > 0.5–0.7 (clearance approaches Qh; sensitive to blood flow changes)\n- **Capacity-limited drugs**: E < 0.3 (clearance sensitive to enzyme activity/protein binding, relatively insensitive to flow)\n\nAt E = 0.67, clearance is substantially dependent on hepatic blood flow. A 50% reduction in Qh would reduce CLh by ~33% (to ~40 L/h), whereas enzyme inhibition would have modest additional effect since extraction is already efficient.", "latency_ms": 4087, "timestamp": "2026-02-10T01:52:57.802005+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|ASSAY-SM-09", "question_id": "ASSAY-SM-09", "pair_id": "ASSAY-09", "category": "Assay Interpretation", "domain": "small_molecule", "question_text": "A PK/PD plot of effect vs plasma concentration shows counterclockwise hysteresis (effect lags concentration early and increases later at the same concentration). What does this imply about system dynamics, and what sampling strategy improves model identifiability?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " ## System Dynamics Implication\n\nCounterclockwise hysteresis indicates **effect site equilibration delay**—the effect compartment (biophase) lags behind plasma concentrations. This occurs when:\n\n- Drug distribution to the site of action is **slower** than plasma kinetics\n- The effect site has distinct PK from central compartment\n- There is a **temporal dissociation** between plasma concentration and observed response\n\nCommon causes include slow blood-tissue perfusion, diffusion barriers, or receptor binding/transduction delays.\n\n## Improved Sampling Strategy\n\nTo enhance model identifiability for **ke0** (effect site equilibration rate constant):\n\n| Strategy | Rationale |\n|----------|-----------|\n| **Dense early sampling** | Capture the rising phase where effect lags concentration most |\n| **Frequent sampling around Tmax** | Characterize the hysteresis loop closure point |\n| **Prolonged sampling** | Observe late-phase convergence when effect catches up to concentration |\n| **Multiple dose levels** | Assess concentration-effect relationship at varying equilibration states |\n\n**Key parameter**: ke0 is best estimated when sampling intervals are **shorter than the half-life of equilibration** (t½,eq = ln(2)/ke0), typically requiring sampling every **15–30 minutes** for drugs with delayed CNS or cardiac effects.\n\nWithout adequate early sampling, ke0 becomes **practically unidentifiable** and collapses toward extreme values.", "latency_ms": 11739, "timestamp": "2026-02-10T01:53:12.541837+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|ADMET-PEP-07", "question_id": "ADMET-PEP-07", "pair_id": "ADMET-07", "category": "ADMET / Pharmacokinetic Properties", "domain": "peptide", "question_text": "Assume renal plasma flow Qr ≈ 45 L/h. A peptide has renal clearance CLr = 5 L/h. Compute extraction ratio E and state whether clearance is more likely flow-limited or capacity/fu-limited.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " ## Calculation\n\n**Extraction ratio (E):**\n$$E = \\frac{CL_r}{Q_r} = \\frac{5 \\text{ L/h}}{45 \\text{ L/h}} = 0.11 \\text{ (or 11\\%)}$$\n\n## Classification\n\nThis clearance is **capacity/fu-limited** (not flow-limited).\n\n## Reasoning\n\n| E value | Classification | Typical characteristics |\n|---------|---------------|------------------------|\n| E > 0.7–0.8 | Flow-limited | High extraction, clearance ≈ blood flow |\n| E < 0.3 | Capacity-limited | Low extraction, clearance depends on fu × CLint |\n\nWith E = 0.11 (well below 0.3), renal clearance of this peptide is **capacity/fu-limited**. This indicates:\n- The peptide is poorly extracted during transit through the kidney\n- Clearance depends primarily on **unbound fraction (fu)** and **intrinsic clearance capacity** rather than delivery rate\n- Common for peptides, which often have low membrane permeability and may be subject to active secretion/reabsorption dynamics", "latency_ms": 8277, "timestamp": "2026-02-10T01:53:23.819832+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|SAR-SM-05", "question_id": "SAR-SM-05", "pair_id": "SAR-05", "category": "SAR Reasoning", "domain": "small_molecule", "question_text": "A ligand’s secondary amide NH donates a hydrogen bond to the target (N–O distance ~2.9 Å) and is critical for potency. What is the expected potency effect of replacing that amide with an ester at the same position, and what other property often changes in parallel?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " ## Expected Potency Effect\n\nReplacing a secondary amide with an ester typically causes a **10- to 100-fold loss in potency** (1–2 orders of magnitude, or ~1.4–2.8 kcal/mol in binding energy).\n\nThis is because:\n- The ester lacks the NH donor, eliminating the critical hydrogen bond to the target\n- The ester carbonyl is a weaker hydrogen bond acceptor than the amide carbonyl\n- The ester oxygen lone pairs have different geometry and reduced H-bond acceptor strength compared to amide carbonyl oxygen\n\n## Parallel Property Change: **Cell Permeability**\n\nAmide-to-ester replacement often increases **passive permeability** and sometimes **oral bioavailability** due to:\n- Masking of the polar NH (reduction in H-bond donors from 1 to 0)\n- Decreased desolvation penalty\n- Increased lipophilicity (typically ΔlogP ~+0.5 to +1.0)\n\nThis creates a classic **potency-permeability trade-off**: esters are frequently used as prodrugs or permeability-enhancing surrogates when the amide NH is not strictly essential for binding, but here—given the described H-bond is \"critical for potency\"—the ester replacement would be expected to substantially weaken target engagement.", "latency_ms": 10805, "timestamp": "2026-02-10T01:53:37.625970+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|GEN-SM-07", "question_id": "GEN-SM-07", "pair_id": "GEN-07", "category": "Generative Design Strategies", "domain": "small_molecule", "question_text": "Give three commonly used synthesizability/developability filters applied to generated small molecules and provide a typical numeric threshold for at least one of them.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " Here are three commonly used synthesizability/developability filters for generated small molecules:\n\n1. **Synthetic Accessibility Score (SAscore)** – estimates ease of synthesis based on fragment contributions and complexity penalties. Typical threshold: **SAscore < 4.5** (lower = more accessible; range 1–10).\n\n2. **Quantitative Estimate of Drug-likeness (QED)** – combines molecular weight, lipophilicity, polarity, solubility, flexibility, and saturation. Typical threshold: **QED > 0.5** (range 0–1, higher = more drug-like).\n\n3. **Retrosynthetic Accessibility Score (RAscore)** – machine learning-based prediction of synthetic feasibility using reaction templates. Typical threshold: **RAscore > 0.5** (probability-like scale 0–1).", "latency_ms": 5446, "timestamp": "2026-02-10T01:53:46.073283+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|SAR-SM-07", "question_id": "SAR-SM-07", "pair_id": "SAR-07", "category": "SAR Reasoning", "domain": "small_molecule", "question_text": "A phenyl ring in a lead compound occupies a hydrophobic pocket in both the intended target and a close off-target homolog. Only the intended target has a nearby Ser OH positioned to hydrogen-bond to a ring heteroatom. What is the expected effect on target potency and selectivity of replacing phenyl with a 3-pyridyl ring (introducing one ring nitrogen), and why?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **Expected Effect: Increased potency at the intended target; increased selectivity over the off-target**\n\n**Mechanism:**\n\n| Parameter | Effect | Rationale |\n|-----------|--------|-----------|\n| **Target potency** | ↑ 2–10× (typical range) | The pyridine N at position 3 can accept a hydrogen bond from the Ser OH, adding a specific binding interaction without significant steric penalty |\n| **Selectivity** | ↑ Significantly | Off-target lacks the Ser OH → no H-bond reward; retains only hydrophobic contribution |\n\n**Key considerations:**\n\n- **3-pyridyl positioning:** The nitrogen must orient toward the Ser OH. If crystal structure or modeling shows the 3-position projects toward the serine, this substitution is optimal. The 2- or 4-pyridyl isomers would likely misdirect the H-bond vector.\n\n- **pKa considerations:** Pyridine N (pKa ~5.2 for conjugate acid) is a weak H-bond acceptor—acceptable for neutral pH binding without protonation issues that would complicate membrane permeability.\n\n- **Desolvation penalty:** Small cost for burying the polar N in the hydrophobic pocket, but typically outweighed by the H-bond gain (~0.5–1.5 kcal/mol net benefit).\n\n- **Off-target binding:** Remains driven primarily by hydrophobic surface area (~80–150 Å² for phenyl/pyridyl), now with a desolvation penalty for the unpaired polar N—potentially *reducing* off-target affinity modestly.\n\n**Bottom line:** This is a classic selectivity strategy—exploiting a conserved hydrophobic feature while adding a target-specific polar interaction.", "latency_ms": 8853, "timestamp": "2026-02-10T01:53:57.927444+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|ADMET-PEP-02", "question_id": "ADMET-PEP-02", "pair_id": "ADMET-02", "category": "ADMET / Pharmacokinetic Properties", "domain": "peptide", "question_text": "A linear peptide is rapidly cleaved by trypsin-like proteases at a Lys site (cleavage after Lys). Name two peptide modifications that typically reduce this cleavage and explain why serum stability increases (include a typical qualitative timescale change).", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " Two peptide modifications that reduce trypsin-like protease cleavage at Lys:\n\n## 1. **N-methylation of the Lys side chain amine**\n- Converts the primary ε-amino group to a secondary amine (dimethyllysine) or tertiary amine (trimethyllysine)\n- Trypsin requires a positively charged primary amine to recognize and bind the Lys residue in its S1 pocket; methylation disrupts this critical ionic interaction with Asp189 of the protease\n- Also sterically hinders access of the catalytic triad to the scissile bond\n\n## 2. **Incorporation of a D-lysine (D-Lys) stereoisomer**\n- Trypsin-like proteases are highly stereospecific for L-amino acids\n- The D-configuration cannot be accommodated in the active site due to spatial incompatibility with the catalytic machinery\n\n## Serum Stability Impact\n\n| Modification | Typical Stability Improvement |\n|-------------|------------------------------|\n| Unmodified linear peptide | **Minutes to hours** (t½ ~5–30 min) |\n| N-methylated or D-amino acid analog | **Hours to days** (t½ ~4–24+ hr) |\n\nThe qualitative increase is typically **10- to 100-fold** longer half-life in serum, transforming rapidly degraded peptides into viable drug candidates.", "latency_ms": 3877, "timestamp": "2026-02-10T01:54:04.805302+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|ADMET-PEP-10", "question_id": "ADMET-PEP-10", "pair_id": "ADMET-10", "category": "ADMET / Pharmacokinetic Properties", "domain": "peptide", "question_text": "Why do small peptides (e.g., 1–5 kDa) often clear rapidly via the kidney, and how does increasing hydrodynamic size (e.g., PEGylation) reduce this clearance?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " Small peptides (1–5 kDa) clear rapidly via the kidney due to **glomerular filtration**. The glomerular filtration barrier—comprising fenestrated endothelium, basement membrane, and podocyte foot processes—allows passage of molecules below ~60–70 kDa, but the cutoff is not absolute. Peptides in the 1–5 kDa range (roughly 10–45 amino acids) fall well below this threshold and are freely filtered into the primary urine at rates approaching renal plasma flow (~600 mL/min in humans). Once filtered, they are either reabsorbed in the proximal tubule (often incompletely) or excreted. The result is typically **half-lives of minutes to a few hours** for unmodified peptides.\n\n**PEGylation increases hydrodynamic size**, typically expanding the effective molecular radius from ~1–2 nm to 5–10 nm or more depending on PEG chain length and architecture. This has two key effects:\n\n1. **Reduced glomerular filtration**: The glomerular barrier becomes increasingly restrictive above ~30–50 kDa hydrodynamic mass. PEGylated proteins/peptides above ~20–30 kDa show markedly reduced filtration; above ~60–70 kDa, filtration becomes negligible.\n\n2. **Increased plasma residence time**: Reduced renal clearance shifts elimination toward slower hepatic or reticuloendothelial pathways. For example, PEGylation of interferon-α (12 kDa native → ~40 kDa PEGylated) extends half-life from ~4 hours to ~40–80 hours (Pegasys®). Similarly, PEGylated granulocyte colony-stimulating factor (G-CSF) shows half-life extension from ~3–4 hours to ~15–80 hours depending on PEG size (Neulasta®).\n\nThe **hydrodynamic radius** matters more than molecular weight per se—PEG is unstructured and occupies a large volume, making it more effective at reducing filtration than globular proteins of equivalent mass.", "latency_ms": 5133, "timestamp": "2026-02-10T01:54:12.939251+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|GEN-SM-01", "question_id": "GEN-SM-01", "pair_id": "GEN-01", "category": "Generative Design Strategies", "domain": "small_molecule", "question_text": "In SMILES-based molecular generation, name three necessary validity conditions a generated string must satisfy to correspond to a chemically valid molecule.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " Three necessary validity conditions for SMILES-based molecular generation:\n\n1. **Syntactic validity** — The string must follow SMILES grammar rules, including proper use of brackets, parentheses, ring closure digits, and valid atom symbols (e.g., \"C\", \"N\", \"[Na+]\", \"[H]\").\n\n2. **Valence compliance** — Each atom must satisfy standard valence rules (e.g., carbon: 4 bonds, neutral nitrogen: 3 bonds, oxygen: 2 bonds). Exceptions require explicit charge/valence specification in brackets.\n\n3. **Structural connectivity** — The molecule must form a single connected structure (or valid ionic/molecular complex with \".\" separators), with properly matched ring closures and balanced parentheses.", "latency_ms": 2453, "timestamp": "2026-02-10T01:54:18.392784+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|SAR-PEP-04", "question_id": "SAR-PEP-04", "pair_id": "SAR-04", "category": "SAR Reasoning", "domain": "peptide", "question_text": "A peptide binds its target as an α-helix, and residue i is buried in a helix-dependent interface. What is the most likely effect on activity of substituting that residue from an L-amino acid to the corresponding D-amino acid, and why?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **Most likely effect: Complete loss of binding/activity**\n\n**Why:**\n\n1. **Helix handedness mismatch**: D-amino acids induce **left-handed helices** (or destabilize right-handed α-helices), while L-amino acids form **right-handed α-helices**. A single D-residue creates a **helix kink or termination**—typically reducing helicity by **2–4 residues** on either side.\n\n2. **Side chain orientation reversal**: In an α-helix, side chains project outward at ~100° intervals. A D-residue at position *i* flips the side chain **~180°** relative to the backbone, pointing the functional group into **opposite steric space**—directly away from the interface it must engage.\n\n3. **Burial penalty**: Since residue *i* is **buried in a helix-dependent interface**, its precise side chain geometry is critical. The D-substitution typically causes **>100-fold** (often **>1000-fold**) affinity loss in protein-protein interaction peptides (e.g., BH3 peptides, coiled-coil inhibitors).\n\n**Quantitative context**: In studies of p53/MDM2 inhibitors and Bcl-2 family helical peptides, single D-substitutions in buried positions routinely reduce IC₅₀ from **nM to >10 µM** or abolish detectable binding entirely.\n\n**Exception**: If the D-residue stabilizes an alternative bioactive conformation (rare) or if the interface tolerates side chain flipping (uncommon for buried positions), partial activity might remain—but this is not the most likely outcome.", "latency_ms": 5339, "timestamp": "2026-02-10T01:54:26.732199+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|ADMET-SM-08", "question_id": "ADMET-SM-08", "pair_id": "ADMET-08", "category": "ADMET / Pharmacokinetic Properties", "domain": "small_molecule", "question_text": "A basic drug has pKa = 9.5 and cLogP = 3.5. At intestinal pH 6.5, approximately what fraction is un-ionized, and what does that imply for passive permeability?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " ## Fraction Un-ionized\n\nFor a basic drug, the fraction un-ionized (fᵤ) is calculated using:\n\n**fᵤ = 1 / (1 + 10^(pKa - pH))**\n\nAt pH 6.5 with pKa 9.5:\n- fᵤ = 1 / (1 + 10^(9.5 - 6.5)) = 1 / (1 + 10³) = **~0.001 or 0.1%**\n\nSo approximately **99.9% is ionized (protonated)** at intestinal pH.\n\n## Implication for Passive Permeability\n\nThis has **major negative implications** for passive permeability:\n\n- The ionized form has extremely low membrane permeability (typically 10⁴–10⁶× lower than un-ionized)\n- Despite favorable lipophilicity (cLogP 3.5), the overwhelming ionization severely restricts passive diffusion\n- Effective permeability is likely **low to moderate** rather than high\n\n## Context\n\nThis exemplifies the **pH-partition hypothesis limitation**: even lipophilic bases often show poor jejunal permeability. However, actual absorption may be rescued by:\n- Active transport (if substrate)\n- Paracellular uptake (small molecules)\n- Higher pH microenvironments at the membrane surface\n- Colonic absorption (pH ~7.4, where fᵤ ≈ 1%)\n\nMany oral basic drugs with pKa > 8–9 show **poor or variable bioavailability** due to this effect.", "latency_ms": 4062, "timestamp": "2026-02-10T01:54:33.795318+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|GEN-PEP-06", "question_id": "GEN-PEP-06", "pair_id": "GEN-06", "category": "Generative Design Strategies", "domain": "peptide", "question_text": "Name two generation-time techniques that increase diversity of generated peptide sequences and one quantitative diversity metric commonly used for sequences.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " Two generation-time techniques that increase peptide sequence diversity:\n\n1. **Temperature sampling** – scaling the softmax logits by a temperature parameter T > 1 flattens the probability distribution, allowing lower-probability amino acids to be sampled more frequently.\n\n2. **Top-k/nucleus (top-p) sampling** – restricting sampling to the k most likely tokens (top-k) or the smallest set whose cumulative probability exceeds p (top-p, typically p = 0.9), combined with random selection within that set, prevents repetitive high-probability sequences.\n\nOne quantitative diversity metric:\n\n**Unique sequences at specified Levenshtein distance** – often reported as the percentage of generated sequences with ≥50% edit distance from the training set or from each other, or as the number of distinct sequences at Hamming/Levenshtein radius r divided by total sequences generated.", "latency_ms": 10850, "timestamp": "2026-02-10T01:54:47.646573+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|SAR-SM-09", "question_id": "SAR-SM-09", "pair_id": "SAR-09", "category": "SAR Reasoning", "domain": "small_molecule", "question_text": "A tertiary amine (pKa ~9) forms a salt bridge to an Asp in the binding site (N–O distance ~2.8 Å). You replace the tertiary amine with an amide at the same position. What is the most likely potency effect and why?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **Potency effect: Significant loss of potency (likely 10- to 1000-fold or more, depending on system)**\n\n**Why:**\n\n| Feature | Tertiary Amine | Amide |\n|--------|---------------|-------|\n| **pKa** | ~9 (protonated at physiological pH) | ~-0.5 to -1 (neutral, non-basic) |\n| **Charge at pH 7.4** | +1 (99.6% protonated) | 0 (neutral) |\n| **Interaction with Asp (pKa ~3.9)** | Strong salt bridge (Coulombic + H-bond) | Weak H-bond acceptor at best |\n\n**Key thermodynamic considerations:**\n\n- Salt bridge contributes **ΔG ≈ -1 to -3 kcal/mol** (strong electrostatic + desolvation penalty offset)\n- Amide-Asp interaction: neutral H-bond, **ΔG ≈ -0.5 to -1.5 kcal/mol** at best; often repulsive due to competing desolvation\n\n**Structural factors:**\n- The 2.8 Å N–O distance is optimal for a charged salt bridge; for a neutral amide, this distance is too short (van der Waals clash likely) and the geometry is unfavorable\n- The amide carbonyl oxygen points away from the Asp carboxylate; the NH is a poor H-bond donor in this context\n\n**Empirical precedent:** Amine-to-amide replacements in protein-ligand interfaces typically cause **ΔΔG of +2 to +5 kcal/mol**, corresponding to **30- to 3000-fold potency loss** (e.g., kinase inhibitors, GPCR ligands, protease inhibitors).\n\nIf the amine was critical for binding (no compensatory interactions), the loss is typically at the higher end of this range.", "latency_ms": 6092, "timestamp": "2026-02-10T01:54:56.739005+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|ADMET-SM-10", "question_id": "ADMET-SM-10", "pair_id": "ADMET-10", "category": "ADMET / Pharmacokinetic Properties", "domain": "small_molecule", "question_text": "What approximate molecular-weight threshold is commonly associated with increased biliary excretion for small molecules, and what other physicochemical features favor biliary vs renal elimination?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " ## Molecular Weight Threshold for Biliary Excretion\n\nThe commonly cited threshold is **~300–500 Da**, with **>500 Da** (or more conservatively **>400–500 Da**) representing the range where biliary excretion becomes increasingly significant. Above **~500 Da**, biliary clearance typically dominates over renal clearance for many compounds.\n\n## Key Physicochemical Features Favoring Biliary vs. Renal Elimination\n\n| Feature | Favors Biliary Excretion | Favors Renal Excretion |\n|--------|------------------------|----------------------|\n| **Molecular weight** | >400–500 Da | <300 Da |\n| **Polarity/LogP** | Moderate lipophilicity (LogP 2–4) | High polarity, hydrophilicity |\n| **Charge** | Anionic (especially at physiological pH); glucuronide/sulfate conjugates | Cationic or neutral small molecules |\n| **Protein binding** | High (>90%), especially to albumin | Low to moderate |\n| **Conjugation** | Presence of glucuronic acid, sulfate, or glutathione conjugation sites | Unconjugated, polar parent drug |\n\n## Additional Considerations\n\n- **Active transport**: Biliary excretion requires recognition by hepatic uptake transporters (OATP, NTCP) and canalicular efflux transporters (BSEP, MRP2, BCRP, P-gp)\n- **Species differences**: Rats show more extensive biliary excretion than humans; human biliary clearance is generally lower and more selective\n- **Molecular weight cutoff for biliary excretion in humans is often considered ~500 Da**, though this is not absolute—highly polar or conjugated compounds may be excreted biliary at lower MW\n\nThe interplay of these factors means some compounds at 400–500 Da may still be renally cleared if sufficiently polar and unbound, while highly lipophilic, protein-bound anions may favor biliary routes even at slightly lower molecular weights.", "latency_ms": 7822, "timestamp": "2026-02-10T01:55:07.561367+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|GEN-SM-10", "question_id": "GEN-SM-10", "pair_id": "GEN-10", "category": "Generative Design Strategies", "domain": "small_molecule", "question_text": "You expand a molecular generator to include non-standard charged fragments (new tokens not seen in the original training set). What two components must be updated to keep generation chemically consistent and valid?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " When expanding a molecular generator with new charged fragment tokens, you must update:\n\n1. **The vocabulary/embedding layer** – to recognize and represent the new tokens numerically (expanded token dictionary, new embedding vectors)\n\n2. **The chemical validity checker or post-processing rules** – to handle valence, charge balance, and bonding constraints specific to these charged species (e.g., ensuring overall molecular neutrality, proper counterion handling, or adjusted valence rules for charged atoms)\n\nIf the generator uses a SMILES/SELFIES grammar or graph-based constraints, the **decoding/grammar rules** may also need modification to ensure syntactically valid outputs with the new tokens.", "latency_ms": 3084, "timestamp": "2026-02-10T01:55:13.645916+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|OPT-SM-05", "question_id": "OPT-SM-05", "pair_id": "OPT-05", "category": "Optimization Approaches", "domain": "small_molecule", "question_text": "A lead compound is cleared rapidly due to oxidative N-dealkylation of a tertiary amine. Propose two structural changes that often reduce this clearance while preserving a basic center, and explain why they work.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " Two effective structural modifications to reduce oxidative N-dealkylation while maintaining basicity:\n\n## 1. **Cyclization of the N-alkyl substituents (forming a cyclic/ring-constrained amine)**\n\nConvert the acyclic tertiary amine to a **cyclic amine** (e.g., pyrrolidine, piperidine, or morpholine ring). \n\n**Why it works:** CYP450-mediated N-dealkylation requires initial hydrogen atom abstraction from the α-carbon of the N-alkyl group. Cyclization restricts conformational freedom and reduces the accessibility of α-C–H bonds to the ferryl oxygen of CYP450. The ring strain and geometric constraints increase the activation energy for the hydrogen atom transfer step. For example, replacing N,N-dimethyl with a pyrrolidine ring typically reduces clearance by **2–5 fold** in many series.\n\n## 2. **Introduction of α-carbon branching or quaternary centers adjacent to nitrogen**\n\nReplace linear N-alkyl chains with **branched alkyl groups** (e.g., isopropyl, tert-butyl, or cycloalkyl) or incorporate the α-carbon into a quaternary center.\n\n**Why it works:** CYP450 N-dealkylation proceeds through a radical rebound mechanism where the rate-limiting step is abstraction of an α-hydrogen. α-Carbon branching: (a) **sterically hinders** approach of the bulky CYP450 active site to the reactive C–H bond, and (b) **weakens the C–H bond strength** paradoxically less relevant than steric effects—more importantly, tertiary α-carbons have **fewer abstractable hydrogens** and increased BDE (bond dissociation energy) for remaining C–H bonds. A classic example: replacing N-methyl with N-isopropyl or N-cyclopropyl can reduce N-dealkylation rates by **>10-fold**, with cyclopropyl being particularly resistant due to ring strain and high α-C–H BDE (~106 kcal/mol vs. ~98 for typical secondary C–H).\n\nBoth modifications preserve the basic nitrogen (pKa typically remains **9–10** for tertiary aliphatic amines), maintaining ionization at physiological pH for target engagement while deflecting metabolic soft spots.", "latency_ms": 6609, "timestamp": "2026-02-10T01:55:23.255326+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|ADMET-SM-02", "question_id": "ADMET-SM-02", "pair_id": "ADMET-02", "category": "ADMET / Pharmacokinetic Properties", "domain": "small_molecule", "question_text": "A benzylic CH2 is identified as the major CYP oxidation soft spot (rapid benzylic hydroxylation). Name one structural change that typically reduces this metabolism and explain the mechanism (include a typical magnitude of intrinsic clearance reduction).", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **Structural change:** Replace the benzylic CH₂ with a gem-dimethyl group (benzylic quaternary carbon) or introduce a fluorine atom at the benzylic position (benzylic CHF or CF₂).\n\n**Mechanism:** \n- **Gem-dimethyl substitution:** Creates a steric block that prevents CYP450 binding/orientation for hydrogen atom abstraction. The benzylic C-H bond is no longer accessible, and the tertiary C-H bonds that remain are significantly stronger (~98-101 kcal/mol vs. ~85-88 kcal/mol for benzylic C-H), making hydrogen abstraction thermodynamically disfavored.\n\n- **Fluorine substitution:** The C-F bond is very strong (~110 kcal/mol) and polarizes the adjacent C-H bonds, increasing their bond dissociation energy. Fluorine also acts as an electron-withdrawing group, reducing the stability of the putative benzylic radical intermediate through destabilization.\n\n**Typical magnitude:** \n- Gem-dimethyl: **5- to >50-fold** reduction in intrinsic clearance (Cl_int), often converting high-clearance compounds to low/moderate clearance.\n- Monofluorination: **3- to 10-fold** reduction common; difluorination can achieve **>10- to 100-fold** reduction.\n\n*Example:* In drug discovery programs, benzylic gem-dimethyl substitution frequently reduces human liver microsome Cl_int from >100 μL/min/mg protein to <20 μL/min/mg protein.", "latency_ms": 32423, "timestamp": "2026-02-10T01:55:58.679041+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|SAR-PEP-03", "question_id": "SAR-PEP-03", "pair_id": "SAR-03", "category": "SAR Reasoning", "domain": "peptide", "question_text": "A linear 10-mer peptide binds a target in a compact turn-like conformation. What is the most likely effect of head-to-tail cyclization on potency and why (assume cyclization does not directly block a key contact residue)?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **Most likely effect: Increased potency**\n\n**Primary reasons:**\n\n1. **Conformational pre-organization**: Cyclization reduces the entropic penalty of binding by constraining the peptide into its bioactive turn conformation. For a 10-mer adopting a compact turn, the effective concentration of the bound-state conformation increases substantially.\n\n2. **Typical magnitude**: Cyclization of linear peptides often improves binding affinity **10- to 1000-fold** (ΔΔG ~1.4–4.1 kcal/mol), with greater benefits for peptides where the bound conformation represents a small fraction of the conformational ensemble.\n\n3. **Proteolytic stability**: Cyclic peptides generally show **10- to 100-fold improved half-lives** in serum, indirectly supporting higher effective concentrations in vivo.\n\n**Key caveat**: The benefit depends on whether cyclization correctly stabilizes the bioactive conformation versus alternative non-productive conformations. If the linker is too short/long or introduces strain, potency may decrease.\n\n**Structural considerations for 10-mers**: Head-to-tail cyclization of a 10-residue peptide creates a 30-membered ring (including backbone atoms), which is readily achievable and often compatible with β-turn or γ-turn stabilization without excessive strain.", "latency_ms": 4008, "timestamp": "2026-02-10T01:56:05.687811+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|SAR-SM-04", "question_id": "SAR-SM-04", "pair_id": "SAR-04", "category": "SAR Reasoning", "domain": "small_molecule", "question_text": "A chiral secondary alcohol is positioned so that only the (S)-enantiomer can donate a hydrogen bond to an Asp residue; the (R)-enantiomer points the substituent into a tight hydrophobic cleft causing steric clash. Which enantiomer is expected to be more potent, and what magnitude of potency difference is commonly observed in such cases?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **(S)-enantiomer** is expected to be more potent.\n\nThis scenario describes a classic **three-point binding** pharmacophore where stereochemistry determines productive versus nonproductive binding geometry.\n\n**Magnitude of potency difference:**\n\n| Scenario | Typical potency ratio (e/a) |\n|----------|----------------------------|\n| Optimal case (one enantiomer optimal, other inactive) | 100–1000× (e/a) |\n| Common range for well-defined stereospecific interactions | 10–100× |\n| Minimum with detectable stereoselectivity | 2–10× |\n\nIn your specific case—where the (R)-enantiomer suffers **both** loss of a critical H-bond **and** incurs steric penalty—the potency difference typically falls in the **30–500× range**, with **~100×** being a reasonable working estimate.\n\n**Key examples:**\n- β-adrenergic antagonists (e.g., propranolol): (S)-enantiomer 100× more potent\n- HIV protease inhibitors: stereochemical requirements at the P2/P1' positions often yield >100× differences\n\nIf the (R)-enantiomer were merely inactive (no binding), the ratio could theoretically approach infinity; however, residual non-specific binding or alternative poses usually limit observed ratios to ~1000× in practice.", "latency_ms": 11359, "timestamp": "2026-02-10T01:56:20.047510+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|ASSAY-SM-02", "question_id": "ASSAY-SM-02", "pair_id": "ASSAY-02", "category": "Assay Interpretation", "domain": "small_molecule", "question_text": "A dose–response curve fit yields a Hill slope of 0.5 (much shallower than 1). Give two mechanistic interpretations relevant to small-molecule assays.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " Two mechanistic interpretations for a Hill slope of 0.5 in small-molecule assays:\n\n1. **Negative cooperativity** — Binding of the first ligand molecule to a multimeric receptor or enzyme reduces the affinity for subsequent binding events (e.g., homodimeric receptors or enzymes with multiple allosteric sites), flattening the response curve.\n\n2. **Multiple independent binding sites with different affinities** — The system contains two or more non-interacting sites (or distinct receptor populations) with substantially different Kd values, producing an apparent shallow slope when responses are pooled.", "latency_ms": 8160, "timestamp": "2026-02-10T01:56:31.208341+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|SAR-PEP-10", "question_id": "SAR-PEP-10", "pair_id": "SAR-10", "category": "SAR Reasoning", "domain": "peptide", "question_text": "A peptide bond adjacent to a Pro residue exists as a cis/trans mixture in solution, but only the trans conformer binds the target. What modification is most likely to increase apparent potency, and why?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **N-methylation of the amide nitrogen adjacent to Pro** (i.e., the residue preceding Pro in the sequence).\n\n**Why this increases apparent potency:**\n\n1. **Thermodynamic bias toward trans**: N-methylation of an Xaa-Pro amide strongly favors the **trans** conformer (typically **>90% trans** vs. ~70-30% trans/cis for unmodified Xaa-Pro in solution). This is due to steric clash between the N-methyl and the Pro Cδ in the cis geometry.\n\n2. **Preorganization effect**: By locking the conformation into the bioactive trans state, you reduce the **conformational entropy penalty** upon binding (estimated **-TΔS contribution of 0.5–2 kcal/mol** for freezing a single rotatable bond). This directly improves binding free energy (ΔG°bind).\n\n3. **Apparent potency increase**: Since only trans binds, the effective concentration of binding-competent species increases from ~70% to >90%, yielding an apparent **IC50 improvement of roughly 1.3- to 3-fold** (greater if the cis→trans interconversion is slow relative to binding kinetics, creating a \"conformational selection\" bottleneck).\n\n**Alternative consideration**: If the Pro itself is modified (e.g., **(4R)- or (4S)-fluoroproline**), this can also bias the preceding amide toward trans via stereoelectronic effects, though N-methylation is generally more direct and reliable for this specific purpose.", "latency_ms": 4587, "timestamp": "2026-02-10T01:56:38.796444+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|OPT-PEP-10", "question_id": "OPT-PEP-10", "pair_id": "OPT-10", "category": "Optimization Approaches", "domain": "peptide", "question_text": "You have four peptides with (EC50 nM, serum half-life h, hemolysis HC50 µg/mL): A(10, 0.2, 50), B(30, 8, 40), C(15, 2, 200), D(50, 20, 20). Objectives: minimize EC50, maximize half-life, maximize HC50. Which peptides are Pareto-optimal?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " I need to find the Pareto-optimal peptides, where no other peptide is better in all three objectives.\n\nLet me define \"better\" for each objective:\n- Lower EC50 is better (minimize)\n- Higher half-life is better (maximize)\n- Higher HC50 is better (maximize)\n\n**Data summary:**\n| Peptide | EC50 (nM) | Half-life (h) | HC50 (µg/mL) |\n|---------|-----------|---------------|--------------|\n| A | 10 | 0.2 | 50 |\n| B | 30 | 8 | 40 |\n| C | 15 | 2 | 200 |\n| D | 50 | 20 | 20 |\n\n**Pairwise dominance checks:**\n\n- **A vs B**: A has better EC50 (10<30) and HC50 (50>40), but worse half-life (0.2<8). Neither dominates.\n- **A vs C**: A has better EC50 (10<15), but worse half-life (0.2<2) and worse HC50 (50<200). Neither dominates.\n- **A vs D**: A has better EC50 (10<50) and HC50 (50>20), but worse half-life (0.2<20). Neither dominates.\n\n- **B vs C**: B has better half-life (8>2), but worse EC50 (30>15) and worse HC50 (40<200). Neither dominates.\n- **B vs D**: B has better EC50 (30<50) and HC50 (40>20), but worse half-life (8<20). Neither dominates.\n\n- **C vs D**: C has better EC50 (15<50) and HC50 (200>20), but worse half-life (2<20). Neither dominates.\n\n**Checking if any peptide is dominated (worse in all three):**\n\n- Is A dominated? No — A has the best EC50 (10 nM), so no peptide can beat it there.\n- Is B dominated? Check: C beats B in EC50 and HC50 but not half-life. D beats B in half-life but not EC50 or HC50. **Not dominated.**\n- Is C dominated? A beats C in EC50 only. B beats C in half-life only. D beats C in half-life only. **Not dominated.**\n- Is D dominated? A beats D in EC50 and HC50. B beats D in EC50 and HC50. C beats D in EC50 and HC50. **Not dominated.**\n\n**Pareto-optimal peptides: A, B, C, D (all four)**\n\nAll four peptides are Pareto-optimal — each represents a different trade-off with no single peptide dominating another across all three objectives.", "latency_ms": 10972, "timestamp": "2026-02-10T01:56:52.768831+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|ADMET-SM-01", "question_id": "ADMET-SM-01", "pair_id": "ADMET-01", "category": "ADMET / Pharmacokinetic Properties", "domain": "small_molecule", "question_text": "State Lipinski’s Rule-of-Five thresholds (MW, cLogP, HBD, HBA) and give two mechanistic reasons why violating multiple thresholds tends to reduce oral exposure.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " ## Lipinski's Rule-of-Five Thresholds\n\n| Parameter | Threshold |\n|-----------|-----------|\n| Molecular weight (MW) | ≤ 500 Da |\n| Calculated lipophilicity (cLogP) | ≤ 5 |\n| Hydrogen bond donors (HBD) | ≤ 5 |\n| Hydrogen bond acceptors (HBA) | ≤ 10 |\n\n---\n\n## Two Mechanistic Reasons for Reduced Oral Exposure\n\n**1. Impaired Intestinal Permeability**\n\n- Excessive HBD/HBA creates a large desolvation penalty for crossing lipid membranes\n- High MW increases molecular cross-sectional area, reducing diffusion through the tight junctions and transcellular routes\n- Combined effect: poor absorption across the intestinal epithelium (typically <10% fraction absorbed for \"beyond Rule-of-5\" compounds)\n\n**2. Increased Hepatic First-Pass Extraction**\n\n- High lipophilicity (cLogP >5) promotes extensive partitioning into hepatocytes and binding to metabolic enzymes (CYPs)\n- Large, lipophilic molecules are often substrates for multiple metabolic pathways\n- Result: elevated hepatic clearance even when absorption occurs, reducing systemic bioavailability", "latency_ms": 17630, "timestamp": "2026-02-10T01:57:13.399857+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|SAR-SM-01", "question_id": "SAR-SM-01", "pair_id": "SAR-01", "category": "SAR Reasoning", "domain": "small_molecule", "question_text": "A ligand’s para-substituent on a phenyl ring points into a hydrophobic subpocket and sits ~3.2 Å from a protein backbone carbonyl oxygen (geometry compatible with a halogen bond). If the para-methyl analog has IC50 = 200 nM, what is the most likely potency change when replacing para-CH3 with para-Cl, and what is the mechanistic rationale?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " ## Predicted Potency Change\n\n**Expected improvement: ~5- to 20-fold (IC₅₀ ~10–40 nM)**\n\n## Mechanistic Rationale\n\n### Halogen Bond Contribution\n- The C–Cl···O=C interaction at 3.2 Å with optimal geometry (θ ~165–180°) provides **ΔG ≈ –0.5 to –1.5 kcal/mol** of binding energy\n- This translates to **4- to 13-fold** potency enhancement at 298 K\n- Methyl cannot form this interaction; its C–H bonds are poor H-bond donors and the geometry is suboptimal for C–H···O contacts\n\n### Additional Factors Favoring Cl\n\n| Factor | Effect |\n|--------|--------|\n| **Size match** | Cl (r ~1.75 Å) vs. CH₃ (r ~2.0 Å) — better subpocket fit |\n| **Hydrophobicity** | Cl (π = 0.06) vs. CH₃ (π = 0.56) — slight desolvation penalty for CH₃ |\n| **Polarizability** | Cl's σ-hole enables directional interaction with carbonyl |\n\n### Caveats\n- If the subpocket is **extremely tight**, Cl's larger van der Waals radius may cause steric clash, attenuating or reversing the gain\n- If the carbonyl oxygen is **already engaged** in a strong H-bond, the halogen bond contribution diminishes\n\n## Literature Benchmark\nSimilar para-substituent swaps in fragment-to-lead optimizations (e.g., in kinase or PDE inhibitors) typically show **5–15× improvements** when a halogen bond replaces a non-interacting group at comparable distances.", "latency_ms": 13063, "timestamp": "2026-02-10T01:57:29.463762+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|ASSAY-PEP-08", "question_id": "ASSAY-PEP-08", "pair_id": "ASSAY-08", "category": "Assay Interpretation", "domain": "peptide", "question_text": "In an in vivo antibacterial study, increasing peptide dose increases plasma exposure linearly but bacterial load reduction plateaus at ~60% and does not improve further. What does this suggest mechanistically, and what is one follow-up measurement to confirm?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " ## Mechanistic Interpretation\n\nThis **exposure-response disconnect** suggests **target-mediated or mechanism-limited efficacy**, not pharmacokinetic limitations. Likely explanations:\n\n| Scenario | Mechanism |\n|----------|-----------|\n| **Most probable** | **Static/bacteriostatic mechanism** — peptide inhibits growth but doesn't kill; ~40% of bacteria remain metabolically dormant or tolerant |\n| **Pharmacodynamic saturation** | Target (e.g., membrane, ribosome) fully engaged; additional drug cannot enhance effect |\n| **Subpopulation resistance** | Persister cells or resistant subset (~40%) unaffected by mechanism |\n| **Compartmentalization** | Drug doesn't reach sanctuary site (e.g., intracellular, biofilm, abscess) |\n\nThe linear PK with plateaued PD rules out **non-linear PK** (e.g., saturable distribution, metabolism) as the cause.\n\n---\n\n## Follow-up Measurement\n\n**Time-kill kinetics at 2-4× the plateau dose** (e.g., if plateau occurs at 10 mg/kg, test 20-40 mg/kg)\n\n- **Bactericidal peptides**: 3-4 log₁₀ CFU reduction, concentration-dependent killing\n- **Bacteriostatic peptides**: <3 log₁₀ reduction, rapid plateau, regrowth after 24h\n\nIf kill kinetics confirm stasis, measure **post-antibiotic effect (PAE)** — static peptides typically show minimal PAE (<2h) versus bactericidal peptides (>4-6h).\n\nAlternative: **Population analysis profiling (PAP)** to quantify resistant subpopulation frequency if heteroresistance suspected.", "latency_ms": 13519, "timestamp": "2026-02-10T01:57:45.984009+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|ASSAY-PEP-07", "question_id": "ASSAY-PEP-07", "pair_id": "ASSAY-07", "category": "Assay Interpretation", "domain": "peptide", "question_text": "Three peptide variants have (EC50 nM, serum stability t1/2 min): A(30, 15), B(80, 240), C(20, 5). If you require EC50 ≤ 50 nM and serum t1/2 ≥ 60 min for the next round, which variant best meets criteria and what is the most logical next step?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **Variant B** best meets the criteria.\n\n**Analysis:**\n| Variant | EC50 (nM) | Pass? | t1/2 (min) | Pass? | Both? |\n|---------|-----------|-------|------------|-------|-------|\n| A | 30 | ✓ | 15 | ✗ | No |\n| B | 80 | ✗ | 240 | ✓ | No |\n| C | 20 | ✓ | 5 | ✗ | No |\n\n**None fully satisfy both criteria.** However, **B is the optimal starting point** because:\n- Its 240 min stability provides substantial margin above the 60 min threshold\n- Its potency (80 nM) is only 1.6× above the 50 nM cutoff—more readily optimizable than A/C's stability deficits (4–12× below threshold)\n\n**Most logical next step:** Structure-activity relationship (SAR) optimization of **B** to improve potency while preserving stability—e.g., conservative substitutions at non-critical residues, cyclization constraints, or N-methylation scans to maintain protease resistance.", "latency_ms": 17963, "timestamp": "2026-02-10T01:58:06.948025+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|GEN-PEP-07", "question_id": "GEN-PEP-07", "pair_id": "GEN-07", "category": "Generative Design Strategies", "domain": "peptide", "question_text": "Give three developability/manufacturability filters applied to generated peptide sequences and provide a typical numeric threshold for at least one (e.g., charge or length).", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " Three common developability/manufacturability filters for peptide sequences:\n\n1. **Net charge at physiological pH** — typically filtered to **−3 to +3** (or narrower, e.g., −2 to +2) to minimize nonspecific binding, aggregation, and formulation challenges.\n\n2. **Peptide length** — often constrained to **≤30–40 amino acids**; longer peptides increasingly resemble protein manufacturing complexities (folding, disulfide bonds, higher production costs).\n\n3. **Hydrophobicity (e.g., GRAVY score or % hydrophobic residues)** — typically filtered to **GRAVY < −0.5 to −1.0** or **<40–50% hydrophobic residues** to reduce aggregation propensity and improve aqueous solubility.\n\nAdditional common filters include: absence of problematic motifs (e.g., N-terminal Gln or Asn, Asp-Pro bonds prone to cleavage), C-terminal amidation feasibility, and predicted aggregation propensity (e.g., Tango or Aggrescan scores below threshold).", "latency_ms": 5685, "timestamp": "2026-02-10T01:58:15.633864+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|ASSAY-PEP-05", "question_id": "ASSAY-PEP-05", "pair_id": "ASSAY-05", "category": "Assay Interpretation", "domain": "peptide", "question_text": "In a mouse efficacy study of a therapeutic peptide dosed weekly, efficacy improves on days 1–3 but wanes by week 3 despite unchanged dosing. Give two plausible assay-linked explanations and name one measurement that distinguishes them.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " Two plausible assay-linked explanations:\n\n1. **Anti-drug antibody (ADA) development** — Mouse immune response generates ADAs by week 2–3 that neutralize the peptide or accelerate its clearance, causing pharmacokinetic (PK) exposure to drop despite consistent dosing.\n\n2. **Target engagement saturation with receptor downregulation/desensitization** — Initial efficacy reflects robust target binding, but sustained peptide exposure triggers receptor internalization, degradation, or signaling pathway adaptation, reducing pharmacodynamic (PD) response even with maintained drug levels.\n\n**Distinguishing measurement:** **Trough serum drug concentration** (or total PK exposure/AUC) at week 3 versus week 1. \n\n- If concentrations are substantially lower → supports ADA-driven clearance (Explanation 1)\n- If concentrations remain comparable → supports receptor/PD adaptation (Explanation 2)", "latency_ms": 3873, "timestamp": "2026-02-10T01:58:22.507401+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|ADMET-PEP-03", "question_id": "ADMET-PEP-03", "pair_id": "ADMET-03", "category": "ADMET / Pharmacokinetic Properties", "domain": "peptide", "question_text": "Name three common drivers of peptide immunogenicity (anti-drug antibody risk) and two mitigation strategies used in therapeutic peptide design.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " ## Three Common Drivers of Peptide Immunogenicity\n\n1. **Foreign sequence content** – Non-human amino acid sequences (e.g., murine or bacterial-derived peptides) or non-natural modifications trigger recognition by naive T cells; >8–10 amino acid differences from human homologs significantly elevate risk\n\n2. **Aggregation and particulate formation** – Aggregates (visible or subvisible, >100 nm) are efficiently taken up by antigen-presenting cells, with risk increasing sharply at aggregate concentrations >0.1% by mass; fibrillar aggregates are particularly immunogenic\n\n3. **T-cell epitope content** – Presence of 9-mer core sequences binding to common HLA-DR alleles (e.g., DRB1*01:01, *04:01, *07:01, *15:01) with predicted IC50 <500 nM; typically 1–3 dominant epitopes drive most responses\n\n---\n\n## Two Mitigation Strategies\n\n| Strategy | Mechanism | Example |\n|----------|-----------|---------|\n| **De-immunization via epitope removal** | Alanine/glycine scanning to disrupt MHC-II binding; computational prediction (e.g., EpiMatrix, NetMHCIIpan) followed by experimental validation | TNF-α inhibitors: replacing T-cell epitopes reduced ADA incidence from ~30% to <5% in some analogs |\n| **PEGylation or lipid conjugation** | Steric shielding reduces proteolytic processing and APC uptake; PEG 20–40 kDa most common | PEGylated interferon-α-2a (Pegasys®): reduced immunogenicity vs. unmodified; note: anti-PEG antibodies now recognized as emerging limitation |\n\n---\n\n**Uncertainty note:** Specific ADA incidence rates vary widely by indication, patient population, and assay sensitivity; the 30%→5% figure represents selected case studies rather than universal outcomes.", "latency_ms": 12631, "timestamp": "2026-02-10T01:58:38.138969+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|OPT-PEP-06", "question_id": "OPT-PEP-06", "pair_id": "OPT-06", "category": "Optimization Approaches", "domain": "peptide", "question_text": "A peptide binds both a target receptor and a homolog. Only the target has a unique Asp near the interface; the homolog has Asn at that position. What sequence modification strategy is most likely to improve selectivity, and why?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " **Strategy: Mutate the peptide to introduce a complementary basic residue (Arg or Lys) at the position that interacts with that Asp.**\n\n**Why this works:**\n\n- Asp (pKa ~3.9) carries a negative charge at physiological pH; Asn (uncharged) cannot form a salt bridge\n- Introducing Arg or Lys creates a **specific electrostatic interaction** with the target's Asp that is absent in the homolog\n- This salt bridge contributes **~1-5 kcal/mol** of binding energy, selectively enhancing target affinity while leaving homolog binding unchanged or reduced\n\n**Alternative/additional approaches:**\n- Introduce a hydrogen bond donor to interact with Asp's side chain carbonyl (Asn lacks this acceptor geometry)\n- Engineer steric clash with Asn's amide group if the homolog position is sensitive to bulk\n\n**Key consideration:** The modification should be positioned to make direct contact with the Asp/Asn side chain, typically within **4-6 Å** for salt bridge formation, confirmed by structural modeling if available.", "latency_ms": 13632, "timestamp": "2026-02-10T01:58:54.771901+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|OPT-PEP-09", "question_id": "OPT-PEP-09", "pair_id": "OPT-09", "category": "Optimization Approaches", "domain": "peptide", "question_text": "A baseline peptide has Kd = 1.0 µM. Mutation A gives Kd = 0.30 µM, mutation B gives Kd = 0.20 µM, and double mutant AB gives Kd = 0.020 µM. Under a multiplicative (log-additive) model, what Kd would you predict for AB, and does the result indicate synergy?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " ## Prediction Under Multiplicative Model\n\nUnder a multiplicative (log-additive) model, the **fold-improvements** from individual mutations combine multiplicatively.\n\n**Step 1: Calculate fold-improvements**\n- Mutation A: 1.0 / 0.30 = **3.3-fold** improvement\n- Mutation B: 1.0 / 0.20 = **5.0-fold** improvement\n\n**Step 2: Predicted Kd for AB**\n- Combined improvement = 3.3 × 5.0 = **16.7-fold**\n- **Predicted Kd = 1.0 µM / 16.7 = 0.060 µM** (or 60 nM)\n\n## Comparison and Synergy Assessment\n\n| | Value |\n|---|---|\n| Predicted (multiplicative) | 0.060 µM |\n| Observed | **0.020 µM** |\n\n**Yes, this indicates synergy.** \n\nThe observed Kd (0.020 µM) is **3-fold better** than the multiplicative prediction (0.060 µM), corresponding to an additional **~1.5 kcal/mol** of binding energy beyond the additive expectation.", "latency_ms": 16617, "timestamp": "2026-02-10T01:59:14.389214+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|OPT-SM-03", "question_id": "OPT-SM-03", "pair_id": "OPT-03", "category": "Optimization Approaches", "domain": "small_molecule", "question_text": "In a QSAR-guided lead-optimization loop, what minimum experimental data characteristics are needed to retrain reliably and reduce overfitting risk?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " For reliable QSAR model retraining in lead optimization with controlled overfitting risk, the minimum experimental data characteristics are:\n\n## Sample Size Requirements\n\n| Model Complexity | Minimum Samples | Preferred |\n|-----------------|-----------------|-----------|\n| Simple (2-3 descriptors) | 15-20 compounds | 30+ |\n| Moderate (5-10 descriptors) | 30-50 compounds | 60-100 |\n| Complex (ML, >10 descriptors) | 50-100 compounds | 200+ |\n\nRule of thumb: **≥5-10 samples per descriptor** (often cited as 5, but 10 is safer)\n\n## Data Quality Characteristics\n\n- **Activity range**: ≥3-4 orders of magnitude in measured potency (pIC₅₀/pKi typically 4-9)\n- **Dynamic range**: Standard deviation of response ≥0.5-1.0 log units\n- **Experimental uncertainty**: CV <15-20% for replicates; documented for weighting\n- **Structural diversity**: Tanimoto similarity <0.7-0.8 across training set (avoid near-duplicates)\n\n## Distribution Requirements\n\n- **Balanced coverage**: No >30% of data clustered in narrow potency range\n- **Representative sampling**: Training set spans chemical space of intended predictions (applicability domain)\n- **Temporal/assay consistency**: Single assay protocol; if multiple batches, include 10-15% overlap compounds\n\n## Validation Minimums\n\n| Validation Type | Minimum Requirement |\n|-----------------|---------------------|\n| Random holdout | 20% or ≥10 compounds |\n| Cross-validation | 5-fold with ≥5 compounds/fold |\n| External test set | 15-20% of total, truly blinded |\n\n## Red Flags for Overfitting\n\n- q² (cross-validated R²) >> r²_pred (external prediction) by >0.2-0.3\n- r² - q² > 0.1 (Golbraikh-Tropsha criteria violation)\n- Standard error of prediction (SEP) >> experimental error\n\n## Practical Lead Optimization Context\n\nIn iterative loops, **prospective validation** is critical: each cycle should include 5-10 synthesized predictions to test model before full commitment. Models with <20 new data points between retraining cycles rarely improve meaningfully—often destabilize.\n\n**Uncertainty**: Exact thresholds vary by endpoint (classification vs. regression), descriptor type (2D vs. 3D), and algorithm. Published \"rules\" (Topliss, Doweyko) derive largely from historical small-molecule datasets; biologics and novel scaffolds may need 2-3× samples.", "latency_ms": 12651, "timestamp": "2026-02-10T01:59:30.041402+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|ASSAY-PEP-09", "question_id": "ASSAY-PEP-09", "pair_id": "ASSAY-09", "category": "Assay Interpretation", "domain": "peptide", "question_text": "Protease degradation of a peptide shows biphasic kinetics: 60% loss in the first 10 minutes, then slow decay over the next 2 hours. Give one kinetic explanation and one experiment that tests it.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " ## Kinetic Explanation: **Two-Compartment/Two-Substrate Model**\n\nThe biphasic kinetics suggests **two distinct peptide populations** with different susceptibilities to protease cleavage:\n\n- **60% \"fast\" component**: Peptide in **unstructured/random coil** conformation or with **exposed cleavage sites** — rapidly degraded (t½ ~5-7 min)\n- **40% \"slow\" component**: Peptide with **stable secondary structure** (α-helix, β-sheet, or proline-rich regions) or **self-associated aggregates** — protected from protease access (t½ >>2 hours)\n\nThe initial rapid phase depletes the accessible fraction, leaving the protected fraction to decay slowly.\n\n---\n\n## Test Experiment: **Circular Dichroism (CD) Spectroscopy + Protease Digestion**\n\n**Procedure:**\n1. Record CD spectrum of intact peptide to assess baseline secondary structure content\n2. Remove aliquots at 10 min, 30 min, 60 min, and 120 min during protease digestion\n3. Quench reactions and analyze remaining peptide by CD and HPLC/MS\n\n**Predicted outcome if hypothesis correct:**\n- At 10 min: CD spectrum shows **increased helical/β-sheet character** relative to t=0 (enrichment of structured fraction)\n- The 40% remaining peptide exhibits **higher molar ellipticity at 222 nm** (α-helix) or **218 nm** (β-sheet) compared to starting material\n- Correlation between structure content and degradation rate: more structure = slower degradation\n\n**Alternative test:** Add **denaturant (2-4 M urea or GdnHCl)** — should accelerate the slow phase by unfolding the protected fraction, collapsing biphasic kinetics to single-phase rapid decay.", "latency_ms": 7772, "timestamp": "2026-02-10T01:59:40.814660+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|OPT-PEP-05", "question_id": "OPT-PEP-05", "pair_id": "OPT-05", "category": "Optimization Approaches", "domain": "peptide", "question_text": "A peptide lead clears rapidly primarily via renal filtration and proteolysis. Name two half-life extension strategies and explain which clearance component each mainly addresses.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " Two half-life extension strategies for this peptide lead:\n\n**1. PEGylation (conjugation to polyethylene glycol)**\n\n- **Mainly addresses: renal filtration**\n- Increases hydrodynamic radius (~2- to 10-fold depending on PEG size), pushing molecular weight above the renal filtration threshold (~30–50 kDa effective size)\n- Example: PEGylated interferon alfa-2a (Pegasys, ~40 kDa) achieves ~90-hour half-life vs. ~4 hours for native form\n\n**2. Fusion to an Fc domain or albumin-binding domain**\n\n- **Mainly addresses: both components, with emphasis on renal filtration**\n- Fc fusion: ~80 kDa total size prevents glomerular filtration; additionally, FcRn recycling protects from proteolysis/lysosomal degradation\n- Example: Fc-fusion peptides like dulaglutide (GLP-1-Fc, ~63 kDa) achieve ~2.5-day half-life vs. ~1.5 minutes for native GLP-1\n\n**Alternative pairing if distinct mechanisms preferred:**\n- **Cyclization/structural constraint** → primarily addresses **proteolysis** (reduces susceptibility to peptidases by limiting conformational flexibility)\n- **Lipidation (e.g., acylation with palmitic acid)** → primarily addresses **renal filtration** (albumin binding increases effective size to ~67 kDa complex; e.g., insulin detemir, liraglutide)", "latency_ms": 6157, "timestamp": "2026-02-10T01:59:49.972657+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|SAR-PEP-07", "question_id": "SAR-PEP-07", "pair_id": "SAR-07", "category": "SAR Reasoning", "domain": "peptide", "question_text": "A peptide binds both a target protein and a close homolog. Only the target has a Tyr OH positioned to hydrogen-bond with a side-chain acceptor at the interface. What is the expected effect on potency and selectivity of substituting a Val at the interface to an Asn (introducing a side-chain carbonyl acceptor), and why?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " ## Expected Effect: Increased Potency and Selectivity\n\n### Potency on Target\n**Increase expected** (potentially 2-10 fold or more, depending on context)\n\n- The Asn side-chain carbonyl (C=O) can now accept a hydrogen bond from the Tyr OH\n- This adds a specific, favorable enthalpic interaction (~0.5–1.5 kcal/mol for a good H-bond)\n- In protein–peptide interfaces, such targeted H-bonds often contribute 5–20× affinity improvements when geometrically optimized\n\n### Selectivity vs. Homolog\n**Substantial increase expected**\n\n- The homolog lacks the Tyr OH, so the Asn substitution introduces an **unpaired polar group** at its interface\n- This creates a desolvation penalty without compensatory H-bond formation\n- The selectivity ratio (target/homolog Kd) could improve **10–100 fold** or more, depending on:\n  - How well the Asn carbonyl is positioned for the Tyr OH\n  - The local environment (burial vs. solvent exposure)\n  - Whether alternative H-bond partners exist in the homolog\n\n### Key Caveats\n| Factor | Risk |\n|--------|------|\n| Asn geometry | Must be compatible with Tyr OH distance (2.8–3.2 Å ideal) and angle |\n| Conformational cost | Asn may restrict peptide flexibility; ΔS penalty possible |\n| Alternative partners | Homolog might have Ser/Thr/Lys that partially compensate |\n\n### Structural Precedent\nThis mirrors successful selectivity engineering in kinase inhibitors (e.g., exploiting unique hinge-binding H-bonds) and in peptide–protein interfaces such as PDZ domains or SH2 domains, where single H-bond differences drive 10–50× selectivity.", "latency_ms": 6788, "timestamp": "2026-02-10T01:59:59.761125+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|ADMET-SM-05", "question_id": "ADMET-SM-05", "pair_id": "ADMET-05", "category": "ADMET / Pharmacokinetic Properties", "domain": "small_molecule", "question_text": "A highly metabolized drug has high intrinsic clearance (CLint >> hepatic blood flow). Using the well-stirred model, how does decreasing the unbound fraction in plasma from fu = 0.01 to fu = 0.005 tend to change hepatic clearance, and why?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " Using the well-stirred model, decreasing unbound fraction (fu) from 0.01 to 0.005 **decreases hepatic clearance** for a highly metabolized drug.\n\n**The well-stirred model equation:**\nCLh = (Qh × fu × CLint) / (Qh + fu × CLint)\n\n**Why this occurs:**\n\nFor high CLint drugs where fu × CLint >> Qh, the equation simplifies to:\nCLh ≈ Qh\n\nHowever, this approximation assumes fu × CLint remains >> Qh. When fu decreases from 0.01 to 0.005:\n\n- The product fu × CLint is halved\n- If fu × CLint was previously >> Qh but now approaches or falls below Qh, the system moves away from the flow-limited condition\n- Hepatic clearance becomes **more dependent on fu × CLint** (the \"capacity\" term) rather than being purely flow-limited\n\n**Quantitative example:**\nIf Qh = 1.5 L/min and CLint = 500 L/min:\n- At fu = 0.01: CLh = (1.5 × 0.01 × 500)/(1.5 + 5) = 7.5/6.5 = **1.15 L/min** (~77% of Qh)\n- At fu = 0.005: CLh = (1.5 × 0.005 × 500)/(1.5 + 2.5) = 3.75/4 = **0.94 L/min** (~63% of Qh)\n\n**Key principle:** Even for high CLint drugs, sufficiently low fu can make hepatic clearance sensitive to changes in protein binding. The drug transitions from flow-limited toward capacity-limited behavior.", "latency_ms": 33388, "timestamp": "2026-02-10T02:00:36.150687+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|ADMET-PEP-06", "question_id": "ADMET-PEP-06", "pair_id": "ADMET-06", "category": "ADMET / Pharmacokinetic Properties", "domain": "peptide", "question_text": "A 12-mer peptide has net charge +3 and many hydrogen-bond donors (backbone + side chains), giving poor cell permeability. Name two chemical strategies that can increase cell permeability while keeping the same amino-acid sequence identity largely intact, and explain why they work.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " Two effective strategies are:\n\n**1. N-methylation of backbone amides**\n- Replace selected N-H groups with N-CH₃ on 2–4 residues, particularly at solvent-exposed positions\n- **Why it works:** Each N-methylation removes a hydrogen-bond donor, reducing desolvation penalty during membrane crossing. It also increases lipophilicity (ΔlogP ~+0.5 per methylation) and disrupts intramolecular H-bonds that stabilize extended conformations. Cyclosporine (11 N-methylations, MW 1,203, cLogP ~2.9) achieves passive permeability despite violating \"Rule of 5\"—a direct demonstration of this principle.\n\n**2. Cyclization via side-chain-to-side-chain or head-to-tail linkers**\n- Form lactams, disulfides, or triazole bridges between appropriately spaced residues (e.g., i to i+4, i to i+7)\n- **Why it works:** Constrains the peptide into a compact, preorganized conformation that reduces the entropic cost of membrane partitioning. Cyclization also shields polar backbone groups from solvent and can bury hydrogen-bond donors in intramolecular contacts. Cyclic peptides like cyclosporine and the cyclomarin anti-tubercular agents show enhanced permeability versus linear analogs; head-to-tail cyclization of an 11-mer HIV protease inhibitor improved Caco-2 permeability 10–100-fold.\n\nBoth strategies preserve the original side-chain functionality critical for target binding while addressing the primary permeability barriers: excessive H-bond donor count and conformational flexibility.", "latency_ms": 18852, "timestamp": "2026-02-10T02:00:58.003148+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|ADMET-PEP-08", "question_id": "ADMET-PEP-08", "pair_id": "ADMET-08", "category": "ADMET / Pharmacokinetic Properties", "domain": "peptide", "question_text": "Some cyclic peptides (~1000–1200 Da) can show measurable oral exposure despite violating Rule-of-Five guidelines. Name three molecular features that enable this and explain the mechanism in terms of effective polarity.", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " Three molecular features that enable oral absorption of cyclic peptides (1000–1200 Da) despite violating Lipinski's Rule-of-Five:\n\n## 1. **Macrocyclic Ring Conformation (Preorganization)**\nThe cyclic backbone restricts conformational freedom, reducing the entropic penalty for membrane permeation. This creates a compact, globular structure that minimizes the solvent-accessible surface area of polar groups. Mechanistically, intramolecular hydrogen bonds (IMHBs) between backbone amides shield polar N-H and C=O groups from water, effectively lowering the **apparent polarity** and reducing the desolvation energy barrier for membrane partitioning.\n\n## 2. **N-Methylation of Backbone Amides**\nStrategic N-methylation removes N-H bond donors (reducing H-bond donor count) and disrupts backbone IMHB networks. This decreases the overall H-bonding capacity with water, lowering the **effective polar surface area (PSA)**. The methyl group also introduces steric bulk that can favor lipophilic conformations. Cyclosporine (11 N-methylations, ~1200 Da) exemplifies this—its PSA is effectively ~140 Å² despite a calculated PSA of ~280 Å² due to extensive IMHBs.\n\n## 3. **Incorporation of Lipophilic Amino Acids/D-Amino Acids**\nSubstitution with lipophilic side chains (e.g., Nle, Cha, Bip) or D-amino acids increases the lipophilic surface area and promotes membrane-compatible conformations. D-amino acids induce β-turn or extended conformations that favor IMHB formation. This shifts the **polarity balance**: the hydrophobic surface fraction increases relative to polar backbone exposure, improving the logP_eff (effective partition coefficient) without substantially increasing molecular weight.\n\n**Mechanistic summary**: These features collectively reduce the **effective polarity** by (a) shielding polar groups via IMHBs, (b) removing polar functionality, and (c) increasing lipophilic surface—enabling these large molecules to mimic smaller, less polar drugs in their membrane permeation behavior.", "latency_ms": 32543, "timestamp": "2026-02-10T02:01:33.547884+00:00", "success": true, "error": null}
{"response_id": "kimi-k2.5:cloud|SAR-SM-08", "question_id": "SAR-SM-08", "pair_id": "SAR-08", "category": "SAR Reasoning", "domain": "small_molecule", "question_text": "A lead compound binds in a folded conformation. You add a gem-dimethyl group adjacent to the folding hinge (Thorpe–Ingold effect) to bias the folded conformation. If conformational preorganization improves binding free energy by ~1.0 kcal/mol, approximately what potency change (fold) would you expect at 298 K, and why?", "model": "Kimi K2.5", "model_tag": "kimi-k2.5:cloud", "response_text": " At 298 K, a ~1.0 kcal/mol improvement in binding free energy (ΔΔG) corresponds to approximately **5- to 6-fold** increase in potency.\n\n**Calculation:**\nUsing ΔG = –RT ln(K), the relationship between free energy and equilibrium constant gives:\n\n$$\\frac{K_{new}}{K_{old}} = e^{-\\Delta\\Delta G / RT} = e^{+1.0 / (0.001987 \\times 298)} = e^{1.69} \\approx 5.4$$\n\nOr using the convenient approximation at 298 K: **ΔΔG (kcal/mol) ≈ –1.36 log(fold change)**, so 1.0 kcal/mol ≈ 0.74 log units ≈ **5.5-fold**.\n\n**Why this matters for the Thorpe–Ingold strategy:**\nThe gem-dimethyl group restricts rotation about the hinge, reducing the entropic penalty of adopting the bioactive conformation. This preorganization improves the effective molarity of the bound conformation without necessarily improving enthalpic interactions. The ~1.0 kcal/mol figure is a well-documented empirical benchmark for such conformational constraints in drug design (e.g., ring closures, gem-dialkyl effects).", "latency_ms": 15962, "timestamp": "2026-02-10T02:01:52.510795+00:00", "success": true, "error": null}
